A A A

News

Pedigrees and I-FP-CIT SPECT scan images of the four families with GCH1 mutations involved in this study.

GCH1 gene and Parkinson's risk

A study published in Brain, led by researchers at UCL Institute of Neurology, has shown that genetic mutations which cause a decrease in dopamine production in the brain and lead to a form of childhood-onset Dystonia, also play a role in the development of Parkinson’s disease.
More...

Leonard Wolfson Experimental Neurology Centre (LWENC)

The new Leonard Wolfson Experimental Neurology Centre (LWENC) has opened for clinical studies and trials

More...

Audioslide presentation on Claudia Manzoni's paper examining how fibroblasts with LRRK2 mutations react to starvation conditions and the possible deficits that they have in autophagy.

LRRK2 and autophagy in fibroblasts

In this paper Claudia Manzoni studies how fibroblast cells from people with Parkinson’s disease caused by mutations in LRRK2 react to starvation. Although the changes are quite subtle, there are differences between the way that fibroblasts that contain mutant LRRK2 respond to being starved – suggesting that there may be changes in the way that these cells regulate a key process called autophagy (a term which comes from the greek meaning to eat yourself, and is one of the ways that cells get rid of waste and recycle proteins and organellles).
More...

Drosophila fly model - University of Sheffield

Genetic mutations linked to Parkinson's disease

Research led by consortium researchers Dr Helene Plun-Favreau (UCL Institute of Neurology) and Dr Alex Whitworth (University of Sheffield), and collaborator Dr Heike Laman (University of Cambridge), has discovered how genetic mutations linked to Parkinson’s disease might play a key role in the death of brain cells, potentially paving the way for the development of more effective drug treatments. In the new study, published in Nature Neuroscience, the team of cross-institutional researchers showed how defects in the Parkinson’s gene Fbxo7 cause problems with mitophagy. More...

Autophagy

LRRK2 and autophagy

Mutations in LRRK2 are the most common genetic cause of Parkinson’s disease. Here, Claudia Manzoni talks about her research (funded by the Rosetrees Trust and the Michael J. Fox Foundation) into what LRRK2 might be doing within the cell: Parkinson’s disease is a brain illness that afflicts 1 in 500 people in the UK. High profile patients, such as the actor Michael J Fox, the boxer Muhammad Ali and the late Pope John Paul II, have raised public awareness of Parkinson’s and its devastating impact. More...

Anthony Schapira

(Principal Investigator)

Tony Schapira


Prof Tony Schapira is the Head of the Department of Clinical Neuroscience at the UCL Institute of Neurology and Chairman of Clinical Neurosciences Specialties.

The primary area of research in the department is the investigation of the aetiology and pathogenesis of neurodegenerative disorders. Specifically the department has an interest in the genetics and biochemistry of Parkinson's disease, Huntington's disease and Friedreich's ataxia. The department has established an international reputation in this area and in the area of diseases of the mitochondrial respiratory chain and inborn errors of mitochondrial function. There are also extensive research programmes on the genetics and pathogenesis of dystonia, motor neurone disease and peripheral nerve disorders. A joint appointment with the Hammersmith Hospital has provided an additional research interest in neuropsychology. Facilities for research are extensive. There are general laboratories for biochemistry, molecular biology, tissue preparation etc, in addition to specialist laboratory space for tissue culture (4 hoods), molecular biology, radioactive work, fluorimetry, spectrophotometry, lipid chemistry and histochemistry. There are advanced facilities for image analysis including an electron microscope.

esearcherID


Contact details

Lab website


Link to Publications RSS button
Jump to: 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 | 1987 | 1986 | 1985 | 1981 | 1980 | 1977 | NULL
Number of items: 574.

2014

Beilina, A; Rudenko, IN; Kaganovich, A; Civiero, L; Chau, H; Kalia, SK; ... Cookson, MR; + view all (2014) Unbiased screen for interactors of leucine-rich repeat kinase 2 supports a common pathway for sporadic and familial Parkinson disease. Proc Natl Acad Sci U S A , 111 (7) 2626 - 2631. 10.1073/pnas.1318306111.

Booth, TC; Nathan, M; Waldman, AD; Quigley, AM; Schapira, AH; Buscombe, J; (2014) The Role of Functional Dopamine-Transporter SPECT Imaging in Parkinsonian Syndromes, Part 2. AJNR Am J Neuroradiol 10.3174/ajnr.A3971.

Booth, TC; Nathan, M; Waldman, AD; Quigley, AM; Schapira, AH; Buscombe, J; (2014) The Role of Functional Dopamine-Transporter SPECT Imaging in Parkinsonian Syndromes, Part 1. AJNR Am J Neuroradiol 10.3174/ajnr.A3970.

Cooper, JM; Wiklander, PB; Nordin, JZ; Al-Shawi, R; Wood, MJ; Vithlani, M; ... Alvarez-Erviti, L; + view all (2014) Systemic exosomal siRNA delivery reduced alpha-synuclein aggregates in brains of transgenic mice. Mov Disord 10.1002/mds.25978.

Dong, J; Gao, J; Nalls, M; Gao, X; Huang, X; Han, J; ... International Parkinson's Disease Genomics Consortium (IPDGC),; + view all (2014) Susceptibility loci for pigmentation and melanoma in relation to Parkinson's disease. Neurobiol Aging , 35 (6) 1512.e5 - 1512.10. 10.1016/j.neurobiolaging.2013.12.020.

Gómez-Sánchez, R; Gegg, ME; Bravo-San Pedro, JM; Niso-Santano, M; Alvarez-Erviti, L; Pizarro-Estrella, E; ... Schapira, AH; + view all (2014) Mitochondrial impairment increases FL-PINK1 levels by calcium-dependent gene expression. Neurobiol Dis , 62 426-440. 10.1016/j.nbd.2013.10.021. Green and gold open access
file

Gkotsi, D; Begum, R; Salt, T; Lascaratos, G; Hogg, C; Chau, KY; ... Jeffery, G; + view all (2014) Recharging mitochondrial batteries in old eyes. Near infra-red increases ATP. Exp Eye Res , 122 pp. 50-53. 10.1016/j.exer.2014.02.023. Green and gold open access
file

Hauser, RA; Gordon, MF; Mizuno, Y; Poewe, W; Barone, P; Schapira, AH; ... Fräßdorf, M; + view all (2014) Minimal clinically important difference in Parkinson's disease as assessed in pivotal trials of pramipexole extended release. Parkinsons Dis , 2014 467131 - ?. 10.1155/2014/467131.

Hauser, RA; Schapira, AH; Barone, P; Mizuno, Y; Rascol, O; Busse, M; ... Pramipexole ER Studies Group,; + view all (2014) Long-term safety and sustained efficacy of extended-release pramipexole in early and advanced Parkinson's disease. Eur J Neurol , 21 (5) 736 - 743.

Kiely, AP; Asi, YT; Kara, E; Limousin, P; Ling, H; Lewis, P; ... Holton, JL; + view all (2014) How do G51D SNCA mutation cases compare clinically and neuropathologically to SNCA duplication and H50Q SNCA mutation? In: NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY. (pp. 11 - 12).

Löhle, M; Ramberg, CJ; Reichmann, H; Schapira, AH; (2014) Early versus delayed initiation of pharmacotherapy in Parkinson's disease. Drugs , 74 (6) 645 - 657. 10.1007/s40265-014-0209-5.

McNeill, A; Magalhaes, J; Shen, C; Chau, KY; Hughes, D; Mehta, A; ... Schapira, AH; + view all (2014) Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells. Brain , 137 (5) pp. 1481-1495. 10.1093/brain/awu020. Green and gold open access
file

McNeill, A; Roberti, G; Lascaratos, G; Hughes, D; Mehta, A; Garway-Heath, DF; Schapira, AHV; (2014) Retinal thinning in Gaucher disease patients and carriers: Results of a pilot study (vol 109, pg 221, 2013). MOLECULAR GENETICS AND METABOLISM , 111 (3) 408 - 408. 10.1016/j.ymgme.2013.12.297.

Nalls, MA; Pankratz, N; Lill, CM; Do, CB; Hernandez, DG; Saad, M; ... Singleton, AB; + view all (2014) Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease. Nat Genet 10.1038/ng.3043.

Proukakis, C; Shoaee, M; Morris, J; Brier, T; Kara, E; Sheerin, UM; ... Schapira, AH; + view all (2014) Analysis of Parkinson's disease brain-derived DNA for alpha-synuclein coding somatic mutations. Mov Disord , 29 (8) 060-1064. 10.1002/mds.25883. Green and gold open access
file

Schapira, AH; (2014) The measurement and importance of non-motor symptoms in Parkinson disease. Eur J Neurol 10.1111/ene.12523.

Schapira, AH; Olanow, CW; Greenamyre, JT; Bezard, E; (2014) Slowing of neurodegeneration in Parkinson's disease and Huntington's disease: future therapeutic perspectives. Lancet 10.1016/S0140-6736(14)61010-2.

Schapira, AH; Patel, S; (2014) Targeting Mitochondria for Neuroprotection in Parkinson Disease. JAMA Neurol 10.1001/jamaneurol.2014.64.

Zokaei, N; McNeill, A; Proukakis, C; Beavan, M; Jarman, P; Korlipara, P; ... Husain, M; + view all (2014) Visual short-term memory deficits associated with GBA mutation and Parkinson's disease. Brain 10.1093/brain/awu143.

2013

Alvarez-Erviti, L; Seow, Y; Schapira, AH; Rodriguez-Oroz, MC; Obeso, JA; Cooper, JM; (2013) Influence of microRNA deregulation on chaperone-mediated autophagy and α-synuclein pathology in Parkinson's disease. Cell Death Dis , 4 e545 - ?. 10.1038/cddis.2013.73. Gold open access

Batla, A; Stamelou, M; Mencacci, N; Schapira, AH; Bhatia, KP; (2013) Ropinirole monotherapy induced severe reversible dyskinesias in Parkinson's disease. Mov Disord , 28 (8) 1159 - 1160. 10.1002/mds.25318. Green and gold open access
file

Beavan, MS; Schapira, AH; (2013) Glucocerebrosidase mutations and the pathogenesis of Parkinson disease. Ann Med , 45 (8) 511 - 521. 10.3109/07853890.2013.849003.

Berg, D; Lang, AE; Postuma, RB; Maetzler, W; Deuschl, G; Gasser, T; ... Stern, M; + view all (2013) Changing the research criteria for the diagnosis of Parkinson's disease: obstacles and opportunities. Lancet Neurol , 12 (5) 514 - 524. 10.1016/S1474-4422(13)70047-4.

Chau, KY; Cooper, JM; Schapira, AH; (2013) Pramipexole reduces phosphorylation of α-Synuclein at Serine-129. Journal of Molecular Neuroscience , 51 pp. 573-580. 10.1007/s12031-013-0030-8. Green and gold open access
filefilefilefilefilefile

Cleeter, MW; Chau, KY; Gluck, C; Mehta, A; Hughes, DA; Duchen, M; ... Schapira, AH; + view all (2013) Glucocerebrosidase inhibition causes mitochondrial dysfunction and free radical damage. Neurochem Int , 62 (1) 1 - 7. 10.1016/j.neuint.2012.10.010. Gold open access

deSouza, RM; Moro, E; Lang, AE; Schapira, AH; (2013) Timing of deep brain stimulation in Parkinson disease: a need for reappraisal? Ann Neurol , 73 (5) 565 - 575. 10.1002/ana.23890. Green and gold open access
file

Duran, R; Mencacci, NE; Angeli, AV; Shoai, M; Deas, E; Houlden, H; ... Foltynie, T; + view all (2013) The glucocerobrosidase E326K variant predisposes to Parkinson's disease, but does not cause Gaucher's disease. Movement Disorders , 28 (2) 232 - 236. 10.1002/mds.25248. Green and gold open access
file

Ferreira, JJ; Katzenschlager, R; Bloem, BR; Bonuccelli, U; Burn, D; Deuschl, G; ... Oertel, WH; + view all (2013) Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson's disease. Eur J Neurol , 20 (1) 5 - 15. 10.1111/j.1468-1331.2012.03866.x.

Holmans, P; Moskvina, V; Jones, L; Sharma, M; International Parkinson's Disease Genomics Consortium,; Vedernikov, A; ... Williams, NM; + view all (2013) A pathway-based analysis provides additional support for an immune-related genetic susceptibility to Parkinson's disease. Hum Mol Genet , 22 (5) 1039 - 1049. 10.1093/hmg/dds492.

Kilpatrick, BS; Eden, ER; Schapira, AH; Futter, CE; Patel, S; (2013) Direct mobilisation of lysosomal Ca2+ triggers complex Ca2+ signals. J Cell Sci , 126 (Pt 1) 60 - 66. 10.1242/jcs.118836.

Klebe, S; Golmard, JL; Nalls, MA; Saad, M; Singleton, AB; Bras, JM; ... Wood, NW; + view all (2013) The Val158Met COMT polymorphism is a modifier of the age at onset in Parkinson's disease with a sexual dimorphism. Journal of Neurology, Neurosurgery and Psychiatry , 84 (6) 666 - 673. 10.1136/jnnp-2012-304475. Green and gold open access
file

Manzoni, C; Mamais, A; Dihanich, S; McGoldrick, P; Devine, MJ; Zerle, J; ... Lewis, PA; + view all (2013) Pathogenic Parkinson's disease mutations across the functional domains of LRRK2 alter the autophagic/lysosomal response to starvation. Biochem Biophys Res Commun 10.1016/j.bbrc.2013.10.159.

Marin, C; Bonastre, M; Mengod, G; Cortés, R; Giralt, A; Obeso, JA; Schapira, AH; (2013) Early L-dopa, but not pramipexole, restores basal ganglia activity in partially 6-OHDA-lesioned rats. Neurobiol Dis 10.1016/j.nbd.2013.12.009.

McNeill, A; Healy, DG; Schapira, AH; Taanman, JW; (2013) Glucosylceramidase degradation in fibroblasts carrying bi-allelic Parkin mutations. Mol Genet Metab 10.1016/j.ymgme.2013.06.002.

McNeill, A; Roberti, G; Lascaratos, G; Hughes, D; Mehta, A; Garway-Heath, DF; Schapira, AH; (2013) Retinal thinning in Gaucher disease patients and carriers: results of a pilot study. Molecular Genetics and Metabolism , 109 (2) 221 - 223. 10.1016/j.ymgme.2013.04.001. Green and gold open access
file

McNeill, A; Wu, RM; Tzen, KY; Aguiar, PC; Arbelo, JM; Barone, P; ... Schapira, AH; + view all (2013) Dopaminergic neuronal imaging in genetic Parkinson's disease: insights into pathogenesis. PLOS ONE , 8 (7) , Article e69190. 10.1371/journal.pone.0069190. Green and gold open access
file

Mullin, S; Schapira, A; (2013) α-Synuclein and mitochondrial dysfunction in Parkinson's disease. Mol Neurobiol , 47 (2) 587 - 597. 10.1007/s12035-013-8394-x.

Nalls, MA; Saad, M; Noyce, AJ; Keller, MF; Schrag, A; Bestwick, JP; ... the United Kingdom Brain Expression Consortium (UKBEC),; + view all (2013) Genetic comorbidities in Parkinson's disease. Hum Mol Genet 10.1093/hmg/ddt465.

Olanow, CW; Schapira, A; (2013) Therapeutic prospects for parkinson's disease. Ann Neurol 10.1002/ana.24011.

Osellame, LD; Rahim, AA; Hargreaves, IP; Gegg, ME; Richard-Londt, A; Brandner, S; ... Duchen, MR; + view all (2013) Mitochondria and quality control defects in a mouse model of Gaucher Disease-links to Parkinson's Disease. Cell Metabolism , 17 (6) pp. 941-953. 10.1016/j.cmet.2013.04.014. Green and gold open access
filefile

Pichler, I; Del Greco, MF; Gogele, M; Lill, CM; Bertram, L; Do, CB; ... Minelli, C; + view all (2013) Serum iron levels and the risk of Parkinson disease: a Mendelian randomization study. PLoS.Med. , 10 (6) , Article e1001462. 10.1371/journal.pmed.1001462. Green and gold open access
file

Proukakis, C; Dudzik, CG; Brier, T; MacKay, DS; Cooper, JM; Millhauser, GL; ... Schapira, AH; + view all (2013) A novel α-synuclein missense mutation in Parkinson disease. Neurology , 80 (11) 1062 - 1064. 10.1212/WNL.0b013e31828727ba.

Proukakis, C; Houlden, H; Schapira, AH; (2013) Somatic alpha-synuclein mutations in Parkinson's disease: Hypothesis and preliminary data. Movement Disorders 10.1002/mds.25502. Green and gold open access
file

Ray Chaudhuri, K; Rojo, JM; Schapira, AH; Brooks, DJ; Stocchi, F; Odin, P; ... Martinez-Martin, P; + view all (2013) A proposal for a comprehensive grading of Parkinson's disease severity combining motor and non-motor assessments: meeting an unmet need. PLoS One , 8 (2) , Article e57221 . 10.1371/journal.pone.0057221. Green and gold open access
file

Sarkozy, A; Hicks, D; Hudson, J; Laval, SH; Barresi, R; Hilton-Jones, D; ... Lochmüller, H; + view all (2013) ANO5 gene analysis in a large cohort of patients with anoctaminopathy: confirmation of male prevalence and high occurrence of the common exon 5 gene mutation. Hum Mutat , 34 (8) 1111 - 1118. 10.1002/humu.22342.

Schapira, AH; (2013) Progress in European neurology 2012-2013. Eur J Neurol , 20 (12) 1499 - 1507. 10.1111/ene.12303.

Schapira, AH; (2013) Recent developments in biomarkers in Parkinson disease. Curr Opin Neurol , 26 (4) 395 - 400. 10.1097/WCO.0b013e3283633741.

Schapira, AH; (2013) Calcium dysregulation in Parkinson's disease. Brain , 136 (Pt 7) 2015 - 2016. 10.1093/brain/awt180.

Schapira, AH; Barone, P; Hauser, RA; Mizuno, Y; Rascol, O; Busse, M; ... Poewe, W; + view all (2013) Success rate, efficacy, and safety/tolerability of overnight switching from immediate- to extended-release pramipexole in advanced Parkinson's disease. Eur J Neurol , 20 (1) 180 - 187. 10.1111/j.1468-1331.2012.03822.x.

Schapira, AH; Barone, P; Hauser, RA; Mizuno, Y; Rascol, O; Busse, M; ... Pramipexole ER Studies Group,; + view all (2013) Patient-reported convenience of once-daily versus three-times-daily dosing during long-term studies of pramipexole in early and advanced Parkinson's disease. Eur J Neurol , 20 (1) 50 - 56. 10.1111/j.1468-1331.2012.03712.x.

Schapira, AH; Gegg, ME; (2013) Glucocerebrosidase in the pathogenesis and treatment of Parkinson disease. Proc Natl Acad Sci U S A , 110 (9) 3214 - 3215. 10.1073/pnas.1300822110.

Schapira, AH; McDermott, MP; Barone, P; Comella, CL; Albrecht, S; Hsu, HH; ... Marek, K; + view all (2013) Pramipexole in patients with early Parkinson's disease (PROUD): a randomised delayed-start trial. Lancet Neurol 10.1016/S1474-4422(13)70117-0.

Schapira, AH; Stocchi, F; Borgohain, R; Onofrj, M; Bhatt, M; Lorenzana, P; ... Study 017 Investigators,; + view all (2013) Long-term efficacy and safety of safinamide as add-on therapy in early Parkinson's disease. Eur J Neurol , 20 (2) 271 - 280. 10.1111/j.1468-1331.2012.03840.x.

Schapira, AHV; (2013) Mitochondrial diseases. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION , 43 1 - 1.

Warren Olanow, C; Kieburtz, K; Rascol, O; Poewe, W; Schapira, AH; Emre, M; ... Stalevo Reduction in Dyskinesia Evaluation in Parkinson's Disease (STRIDE-PD) Investigators,; + view all (2013) Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease. Mov Disord , 28 (8) 1064 - 1071. 10.1002/mds.25364.

2012

Cnop, M; Igoillo-Esteve, M; Rai, M; Begu, A; Serroukh, Y; Depondt, C; ... Féry, F; + view all (2012) Central role and mechanisms of β-cell dysfunction and death in friedreich ataxia-associated diabetes. Ann Neurol , 72 (6) 971 - 982. 10.1002/ana.23698.

Devine, MJ; Kaganovich, A; Ryten, M; Mamais, A; Trabzuni, D; Manzoni, C; ... Lewis, PA; + view all (2012) Correction: Pathogenic LRRK2 Mutations Do Not Alter Gene Expression in Cell Model Systems or Human Brain Tissue. PLOS ONE , 7 (1) , Article e22489. 10.1371/annotation/c12e4f9e-5aae-424b-a69f-fddf16976dc5. Green and gold open access
file

Duran, R; McNeill, A; Mehta, A; Hughes, D; Cox, T; Deegan, P; ... Hardy, J; + view all (2012) Novel pathogenic mutations in the glucocerebrosidase locus. Mol Genet Metab , 106 (4) 495 - 497. 10.1016/j.ymgme.2012.05.006. Gold open access

Gardiner, AR; Bhatia, KP; Stamelou, M; Dale, RC; Kurian, MA; Schneider, SA; ... Houlden, H; + view all (2012) PRRT2 gene mutations: from paroxysmal dyskinesia to episodic ataxia and hemiplegic migraine. Neurology , 79 (21) 2115 - 2121. 10.1212/WNL.0b013e3182752c5a.

Gegg, ME; Burke, D; Heales, SJ; Cooper, JM; Hardy, J; Wood, NW; Schapira, AH; (2012) Glucocerebrosidase deficiency in substantia nigra of parkinson disease brains. Ann Neurol , 72 (3) 455 - 463. 10.1002/ana.23614.

Keller, MF; Saad, M; Bras, J; Bettella, F; Nicolaou, N; Simón-Sánchez, J; ... Wellcome Trust Case Control Consortium 2 (WTCCC2),; + view all (2012) Using genome-wide complex trait analysis to quantify 'missing heritability' in Parkinson's disease. Hum Mol Genet , 21 (22) 4996 - 5009. 10.1093/hmg/dds335.

Klionsky, DJ; Abdalla, FC; Abeliovich, H; Abraham, RT; Acevedo-Arozena, A; Adeli, K; ... Zuckerbraun, B; + view all (2012) Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy , 8 (4) 445 - 544.

Lascaratos, G; Garway-Heath, DF; Willoughby, CE; Chau, KY; Schapira, AH; (2012) Mitochondrial dysfunction in glaucoma: understanding genetic influences. Mitochondrion , 12 (2) 202 - 212. 10.1016/j.mito.2011.11.004.

McNeill, A; Duran, R; Hughes, DA; Mehta, A; Schapira, AH; (2012) A clinical and family history study of Parkinson's disease in heterozygous glucocerebrosidase mutation carriers. [Letter]. Journal of Neurology, Neurosurgery & Psychiatry , 83 (8) 853 -854. 10.1136/jnnp-2012-302402. Green and gold open access
file

McNeill, A; Duran, R; Proukakis, C; Bras, J; Hughes, D; Mehta, A; ... Schapira, AH; + view all (2012) Hyposmia and cognitive impairment in Gaucher disease patients and carriers. Mov Disord , 27 (4) 526 - 532. 10.1002/mds.24945.

Mittag, F; Büchel, F; Saad, M; Jahn, A; Schulte, C; Bochdanovits, Z; ... International Parkinson’s Disease Genomics Consortium,; + view all (2012) Use of support vector machines for disease risk prediction in genome-wide association studies: concerns and opportunities. Hum Mutat , 33 (12) 1708 - 1718. 10.1002/humu.22161.

Mizuno, Y; Yamamoto, M; Kuno, S; Hasegawa, K; Hattori, N; Kagimura, T; ... Pramipexole ER Study Group,; + view all (2012) Efficacy and safety of extended- versus immediate-release pramipexole in Japanese patients with advanced and L-dopa-undertreated Parkinson disease: a double-blind, randomized trial. Clin Neuropharmacol , 35 (4) 174 - 181. 10.1097/WNF.0b013e31825f77b9.

Osellame, LD; Rahim, A; Gegg, ME; Waddington, S; Schapira, AHV; Duchen, MR; (2012) Accumulation of damaged mitochondria in neuropathic Gaucher disease, the most prevalent risk factor for Parkinson's disease, is due to defective cellular degradation machinery. In: BIOCHIMICA ET BIOPHYSICA ACTA-BIOENERGETICS. (pp. S79 - S80).

Papkovskaia, TD; Chau, KY; Inesta-Vaquera, F; Papkovsky, DB; Healy, DG; Nishio, K; ... Cooper, JM; + view all (2012) G2019S leucine-rich repeat kinase 2 causes uncoupling protein-mediated mitochondrial depolarization. Hum Mol Genet , 21 (19) 4201 - 4213. 10.1093/hmg/dds244. Gold open access

Schapira, AH; (2012) Mitochondrial diseases. Lancet , 379 (9828) 1825 - 1834. 10.1016/S0140-6736(11)61305-6.

Schapira, AH; (2012) Targeting mitochondria for neuroprotection in Parkinson's disease. Antioxid Redox Signal , 16 (9) 965 - 973. 10.1089/ars.2011.4419.

Schapira, AH; Hillbom, M; (2012) Advances in neurology 2011-12. Eur J Neurol , 19 (10) 1267 - 1275. 10.1111/j.1468-1331.2012.03870.x.

Schapira, AH; Tan, EK; (2012) Optimizing treatment for Parkinson's disease. Eur J Neurol , 19 (12) 1483 - 1486. 10.1111/ene.12025.

Stocchi, F; Borgohain, R; Onofrj, M; Schapira, AH; Bhatt, M; Lucini, V; ... Study 015 Investigators,; + view all (2012) A randomized, double-blind, placebo-controlled trial of safinamide as add-on therapy in early Parkinson's disease patients. Mov Disord , 27 (1) 106 - 112. 10.1002/mds.23954.

Wray, S; Self, M; NINDS Parkinson's Disease iPSC Consortium,; NINDS Huntington's Disease iPSC Consortium,; NINDS ALS iPSC Consortium,; Lewis, PA; ... Hardy, J; + view all (2012) Creation of an open-access, mutation-defined fibroblast resource for neurological disease research. PLOS One , 7 (8) , Article e43099. 10.1371/journal.pone.0043099. Green and gold open access
file

2011

Abramov, AY; Gegg, M; Grunewald, A; Wood, NW; Klein, C; Schapira, AHV; (2011) Bioenergetic Consequences of PINK1 Mutations in Parkinson Disease. PLOS ONE , 6 (10) , Article e25622. 10.1371/journal.pone.0025622. Green and gold open access
file

Alvarez-Erviti, L; Seow, Y; Schapira, AH; Gardiner, C; Sargent, IL; Wood, MJA; Cooper, JM; (2011) Lysosomal dysfunction increases exosome-mediated alpha-synuclein release and transmission. NEUROBIOL DIS , 42 (3) 360 - 367. 10.1016/j.nbd.2011.01.029. Gold open access

Brainin, M; Berardelli, A; Boon, P; Gilhus, NE; Leys, D; Ludolph, A; ... EFNS Sci Comm,; + view all (2011) Comment from the EFNS Scientific Committee on the letter from Gunther Haag concerning Bendsten L et al. EFNS guideline on the treatment of tension-type headache - report of an EFNS task force. Eur J Neurol 2010; 17: 1318-1325. EUR J NEUROL , 18 (7) E83 - E84. 10.1111/j.1468-1331.2011.03382.x.

Devine, MJ; Kaganovich, A; Ryten, M; Mamais, A; Trabzuni, D; Manzoni, C; ... Lewis, PA; + view all (2011) Pathogenic LRRK2 Mutations Do Not Alter Gene Expression in Cell Model Systems or Human Brain Tissue. PLOS ONE , 6 (7) , Article e22489. 10.1371/journal.pone.0022489. Green and gold open access
file

Devine, MJ; Ryten, M; Vodicka, P; Thomson, AJ; Burdon, T; Houlden, H; ... Kunath, T; + view all (2011) Parkinson's disease induced pluripotent stem cells with triplication of the alpha-synuclein locus. NAT COMMUN , 2 , Article 440. 10.1038/ncomms1453. Gold open access

Gegg, ME; Schapira, AHV; (2011) PINK1-parkin-dependent mitophagy involves ubiquitination of mitofusins 1 and 2 Implications for Parkinson disease pathogenesis. AUTOPHAGY , 7 (2) 243 - 245. 10.4161/auto.7.2.14332.

Meissner, WG; Frasier, M; Gasser, T; Goetz, CG; Lozano, A; Piccini, P; ... Bezard, E; + view all (2011) Priorities in Parkinson's disease research. Nat Rev Drug Discov , 10 (5) 377 - 393. 10.1038/nrd3430.

Plagnol, V; Nalls, MA; Bras, JM; Hernandez, DG; Sharma, M; Sheerin, UM; ... WTCCC2,; + view all (2011) A Two-Stage Meta-Analysis Identifies Several New Loci for Parkinson's Disease. PLoS Genetics , 7 (6) , Article e1002142. 10.1371/journal.pgen.1002142. Green and gold open access
file

Poewe, W; Rascol, O; Barone, P; Hauser, RA; Mizuno, Y; Haaksma, M; ... Pramipexole ER Studies Grp,; + view all (2011) Extended-release pramipexole in early Parkinson disease A 33-week randomized controlled trial. NEUROLOGY , 77 (8) 759 - 766.

Schapira, AH; (2011) Monoamine oxidase B inhibitors for the treatment of Parkinson's disease: a review of symptomatic and potential disease-modifying effects. CNS Drugs , 25 (12) 1061 - 1071. 10.2165/11596310-000000000-00000.

Schapira, AH; (2011) Mitochondrial pathology in Parkinson's disease. Mt Sinai J Med , 78 (6) 872 - 881. 10.1002/msj.20303.

Schapira, AH; (2011) Aetiopathogenesis of Parkinson's disease. J Neurol , 258 (Suppl 2) S307 - S310. 10.1007/s00415-011-6016-y.

Schapira, AH; Gegg, M; (2011) Mitochondrial contribution to Parkinson's disease pathogenesis. Parkinson's Disease , 2011 , Article 159160. 10.4061/2011/159160. Green and gold open access
file

Schapira, AH; Hillbom, M; (2011) Publishing changes and information delivery in the clinical neurosciences. Eur J Neurol , 18 (12) 1365 - 1372. 10.1111/j.1468-1331.2011.03594.x.

Schapira, AH; Jenner, P; (2011) Etiology and Pathogenesis of Parkinson's Disease. MOVEMENT DISORD , 26 (6) 1049 - 1055. 10.1002/mds.23732.

Schapira, AHV; (2011) Challenges to the development of disease-modifying therapies in Parkinson's disease. EUR J NEUROL , 18 16 - 21. 10.1111/j.1468-1331.2010.03324.x.

Schapira, AHV; (2011) The management of Parkinson's disease - what is new? EUR J NEUROL , 18 1 - 2. 10.1111/j.1468-1331.2010.03323.x.

Schapira, AHV; Barone, P; Hauser, RA; Mizuno, Y; Rascol, O; Busse, M; ... Pramipexole ER Studies Grp,; + view all (2011) Extended-release pramipexole in advanced Parkinson disease A randomized controlled trial. NEUROLOGY , 77 (8) 767 - 774.

Schapira, AHV; Schrag, A; (2011) Parkinson disease clinical subtypes and their implications. NAT REV NEUROL , 7 (5) 247 - 248. 10.1038/nrneurol.2011.40.

Sivam, D; Rizos, A; Martin, A; Naidu, Y; Renton, T; Schapira, AHV; ... Chaudhuri, KR; + view all (2011) Pain in Parkinson's disease: Observational study of 225 patients. In: MOVEMENT DISORDERS. (pp. S182 - S182).

Stocchi, F; Giorgi, L; Hunter, B; Schapira, AHV; (2011) PREPARED: Comparison of Prolonged and Immediate Release Ropinirole in Advanced Parkinson's Disease. MOVEMENT DISORD , 26 (7) 1259 - 1265. 10.1002/mds.23498.

Tan, EK; Schapira, AH; (2011) LRRK2 as a therapeutic target in Parkinson's disease. EUR J NEUROL , 18 (4) 545 - 546. 10.1111/j.1468-1331.2010.03305.x.

Tan, EK; Schapira, AH; (2011) New LRRK2 variants identified in Parkinson's disease. EUR J NEUROL , 18 (3) 369 - 370. 10.1111/j.1468-1331.2010.03163.x.

2010

Schapira, AH and Fahn, S and Lang, AET (Eds). (2010) Movement Disorders 4: Blue Book Neurology Series. (Vol.34). Elsevier Health Sciences

Alvarez-Erviti, L; Rodriguez-Oroz, MC; Cooper, JM; Caballero, C; Ferrer, I; Obeso, JA; Schapira, AHV; (2010) Chaperone-Mediated Autophagy Markers in Parkinson Disease Brains. ARCH NEUROL-CHICAGO , 67 (12) 1464 - 1472. 10.1001/archneuro1.2010.198.

Chau, KY; Cooper, JM; Schapira, AHV; (2010) Rasagiline protects against alpha-synuclein induced sensitivity to oxidative stress in dopaminergic cells. NEUROCHEM INT , 57 (5) 525 - 529. 10.1016/j.neuint.2010.06.017.

Chaudhuri, KR; Prieto-Jurcynska, C; Naidu, Y; Mitra, T; Frades-Payo, B; Tluk, S; ... Martinez-Martin, P; + view all (2010) The Nondeclaration of Nonmotor Symptoms of Parkinson's Disease to Health Care Professionals: An International Study Using the Nonmotor Symptoms Questionnaire. MOVEMENT DISORD , 25 (6) 704 - 709. 10.1002/mds.22868.

Gegg, ME; Cooper, JM; Chau, KY; Rojo, M; Schapira, AHV; Taanman, JW; (2010) Mitofusin 1 and mitofusin 2 are ubiquitinated in a PINK1/parkin-dependent manner upon induction of mitophagy. HUM MOL GENET , 19 (24) 4861 - 4870. 10.1093/hmg/ddq419.

Grunewald, A; Voges, L; Rakovic, A; Kasten, M; Kock, N; Schapira, AHV; ... Klein, C; + view all (2010) Impact of Mutations in Parkin on Mitochondrial Function and Morphology. In: NEUROLOGY. (pp. A261 - A261). LIPPINCOTT WILLIAMS & WILKINS

Grunewald, A; Voges, L; Rakovic, A; Kasten, M; Vandebona, H; Hemmelmann, C; ... Klein, C; + view all (2010) Mutant Parkin Impairs Mitochondrial Function and Morphology in Human Fibroblasts. PLOS ONE , 5 (9) , Article e12962. 10.1371/journal.pone.0012962. Green and gold open access
file

Hauser, RA; Schapira, AHV; Rascol, O; Barone, P; Mizuno, Y; Salin, L; ... Poewe, W; + view all (2010) Randomized, Double-Blind, Multicenter Evaluation of Pramipexole Extended Release Once Daily in Early Parkinson's Disease. MOVEMENT DISORD , 25 (15) 2542 - 2549. 10.1002/mds.23317.

Kajihara, M; Montagnese, S; Khanna, P; Amodio, P; Schapira, AH; Dusheiko, GM; Morgan, MY; (2010) Parkinsonism in patients with chronic hepatitis C treated with interferon-alpha2b: a report of two cases. Eur.J.Gastroenterol.Hepatol. , 22 (5) 628 - 631.

Kajihara, M; Montagnese, S; Khanna, P; Amodio, P; Schapira, AHV; Dusheiko, GM; Morgan, MY; (2010) Parkinsonism in patients with chronic hepatitis C treated with interferon-alpha 2b: a report of two cases. EUR J GASTROEN HEPAT , 22 (5) 628 - 631. 10.1097/MEG.0b013e32833383e3.

Obeso, JA; Rodriguez-Oroz, MC; Goetz, CG; Marin, C; Kordower, JH; Rodriguez, M; ... Halliday, G; + view all (2010) Missing pieces in the Parkinson's disease puzzle. NAT MED , 16 (6) 653 - 661.

Rajagopalan, B; Francis, JM; Cooke, F; Korlipara, LVP; Blamire, AM; Schapira, AHV; ... Cooper, JM; + view all (2010) Analysis of the Factors Influencing the Cardiac Phenotype in Friedreich's Ataxia. MOVEMENT DISORD , 25 (7) 846 - 852. 10.1002/mds.22864.

Rascol, O; Barone, P; Hauser, RA; Mizuno, Y; Poewe, W; Schapira, AHV; ... Pramipexole Switch Study Grp,; + view all (2010) Efficacy, Safety, and Tolerability of Overnight Switching from Immediate- to Once Daily Extended-Release Pramipexole in Early Parkinson's Disease. MOVEMENT DISORD , 25 (14) 2326 - 2332. 10.1002/mds.23262.

Schapira, A; (2010) Parkinson's Disease in Daily Practice. John Wiley & Sons Inc

Schapira, AHV; (2010) Safinamide in the treatment of Parkinson's disease. EXPERT OPIN PHARMACO , 11 (13) 2261 - 2268. 10.1517/14656566.2010.511612.

Schapira, AHV; (2010) Complex I: Inhibitors, inhibition and neurodegeneration. EXP NEUROL , 224 (2) 331 - 335. 10.1016/j.expneurol.2010.03.028.

Schapira, AHV; (2010) Movement disorders: advances in cause and treatment. LANCET NEUROL , 9 (1) 6 - 7.

Schapira, AHV; (2010) Future Strategies for Neuroprotection in Parkinson's Disease. NEURODEGENER DIS , 7 (1-3) 210 - 212. 10.1159/000295666.

Schapira, AHV; Albrecht, S; Barone, P; Comella, CL; McDermott, MP; Mizuno, Y; ... Marek, K; + view all (2010) Rationale for Delayed-Start Study of Pramipexole in Parkinson's Disease: The PROUD Study. MOVEMENT DISORD , 25 (11) 1627 - 1632. 10.1002/mds.23143.

Schapira, AHV; Barone, P; Hauser, RA; Mizuno, Y; Rascol, O; Busse, M; ... Pramipexole ER Studies Grp,; + view all (2010) Comparisons among responses to pramipexole extended-release as adjunctive treatment in Japanese and non-Japanese studies of advanced Parkinson's disease. In: EUROPEAN JOURNAL OF NEUROLOGY. (pp. 374 - 374). WILEY-BLACKWELL

Schapira, AHV; Barone, P; Hauser, RA; Mizuno, Y; Rascol, O; Busse, M; ... Pramipexole ER Studies Grp,; + view all (2010) Sustained off-time decrease in patients using pramipexole extended-release as adjunctive treatment in advanced Parkinson's disease. In: EUROPEAN JOURNAL OF NEUROLOGY. (pp. 100 - 100). WILEY-BLACKWELL

Schapira, AHV; Barone, P; Hauser, RA; Mizuno, Y; Rascol, O; Busse, M; ... Pramipexole ER Studies Grp,; + view all (2010) Sustained efficacy and tolerability of pramipexole extended-release as adjunctive treatment in advanced Parkinson's disease. In: MOVEMENT DISORDERS. (pp. S309 - S309). WILEY-LISS

Schapira, AHV; Fox, S; Hauser, R; Jankovic, J; Kulisevsky, J; Pahwa, R; ... Musch, B; + view all (2010) SETTLE study design: A 24-week, double-blind, placebo-controlled study of the efficacy and safety of safinamide as add-on therapy to levodopa in patients with Parkinson's diseases Add-On Therapy to Levodopa in Patients with Parkinson's disease. In: MOVEMENT DISORDERS. (pp. S308 - S309). WILEY-LISS

Schapira, AHV; Tolosa, E; (2010) Molecular and clinical prodrome of Parkinson disease: implications for treatment. NAT REV NEUROL , 6 (6) 309 - 317. 10.1038/nrneurol.2010.52.

Tan, EK; Schapira, AH; (2010) Summary of GIGYF2 studies in Parkinson's disease: the burden of proof. EUR J NEUROL , 17 (2) 175 - 176. 10.1111/j.1468-1331.2009.02834.x.

Turner, C; Schapira, AHV; (2010) Mitochondrial matters of the brain: the role in Huntington's disease. J BIOENERG BIOMEMBR , 42 (3) 193 - 198. 10.1007/s10863-010-9290-y.

2009

Bhattacharyya, S; Schapira, AH; Mikhailidis, DP; Davar, J; (2009) Drug-induced fibrotic valvular heart disease. LANCET , 374 (9689) 577 - 585.

Cano, SJ; Riazi, A; Schapira, AHV; Cooper, JM; Hobart, JC; (2009) Friedreich's Ataxia Impact Scale: A New Measure Striving to Provide the Flexibility Required by Today's Studies. MOVEMENT DISORD , 24 (7) 984 - 992. 10.1002/mds.22420.

Chau, KY; Ching, HL; Schapira, AHV; Cooper, JM; (2009) Relationship between alpha synuclein phosphorylation, proteasomal inhibition and cell death: relevance to Parkinson's disease pathogenesis. J NEUROCHEM , 110 (3) 1005 - 1013. 10.1111/j.1471-4159.2009.06191.x.

Chau, KY; Korlipara, LVP; Cooper, JM; Schapira, AHV; (2009) Protection against paraquat and A53T alpha-synuclein toxicity by cabergoline is partially mediated by dopamine receptors. J NEUROL SCI , 278 (1-2) 44 - 53. 10.1016/j.jns.2008.11.012.

Chaudhuri, KR; Martinez-Martin, P; Sherman, R; Naidu, Y; Odin, P; Sethi, K; ... PD Non Motor Grp,; + view all (2009) The Non Motor Staging of Parkinson's Disease: Results from an International Study. In: NEUROLOGY. (pp. A322 - A322). LIPPINCOTT WILLIAMS & WILKINS

Chaudhuri, KR; Schapira, AHV; (2009) Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment. LANCET NEUROL , 8 (5) 464 - 474.

Gallagher, DA; Schapira, AHV; (2009) Etiopathogenesis and Treatment of Parkinson's Disease. CURR TOP MED CHEM , 9 (10) 860 - 868.

Gegg, ME; Cooper, JM; Schapira, AHV; Taanman, JW; (2009) Silencing of PINK1 Expression Affects Mitochondrial DNA and Oxidative Phosphorylation in DOPAMINERGIC Cells. PLOS ONE , 4 (3) , Article e4756. 10.1371/journal.pone.0004756. Green and gold open access
file

Grunewald, A; Gegg, ME; Taanman, JW; King, RH; Kock, N; Klein, C; Schapira, AHV; (2009) Differential effects of PINK1 nonsense and missense mutations on mitochondrial function and morphology. EXP NEUROL , 219 (1) 266 - 273. 10.1016/j.expneurol.2009.05.027.

Martinez-Martin, P; Sherman, R; Naidu, Y; Richards, C; Odin, P; Stocchi, F; ... Chaudhuri, KR; + view all (2009) Non- motor staging of Parkinson's disease (PD) and early longitudinal follow up results from an international study. In: MOVEMENT DISORDERS. (pp. S385 - S385). WILEY-LISS

Naidu, Y; Martinez-Martin, P; Mitra, T; Tluk, S; Stocchi, F; Macphee, G; ... Chaudhuri, KR; + view all (2009) Non declaration of non motor symptoms (NMS) of PD: An international study using the NMSQuest. In: MOVEMENT DISORDERS. (pp. S386 - S386). WILEY-LISS

Nissinen, H; Kuoppamaki, M; Leinonen, M; Schapira, AH; (2009) Early versus delayed initiation of entacapone in levodopa-treated patients with Parkinson's disease: a long-term, retrospective analysis. EUR J NEUROL , 16 (12) 1305 - 1311. 10.1111/j.1468-1331.2009.02726.x.

Obeso, JA; Schapira, AH; (2009) Compensatory Mechanisms in Parkinson's Disease. MOVEMENT DISORD , 24 (1) 153 - 154. 10.1002/mds.22177.

Reddy, P; Naidu, Y; Suleyman, N; Tluk, S; Odin, P; Macphee, G; ... Chaudhuri, KR; + view all (2009) Characterisation of Restless Legs like syndrome in Parkinson's disease. In: MOVEMENT DISORDERS. (pp. S375 - S375). WILEY-LISS

Schapira, A; Hartmann, A; Agid, Y; (2009) Parkinsonian Disorders in Clinical Practice. Wiley-Blackwell

Schapira, A; Hartmann, A; Agid, Y; (2009) Parkinsonian Disorders in Clinical Practice. Whiley Blackwell

Schapira, AH; Agid, Y; Barone, P; Jenner, P; Lemke, MR; Poewe, W; ... Tolosa, E; + view all (2009) Perspectives on recent advances in the understanding and treatment of Parkinson's disease. EUR J NEUROL , 16 (10) 1090 - 1099. 10.1111/j.1468-1331.2009.02793.x.

Schapira, AH; Olanow, CW; (2009) Initiating Therapy in Parkinson's Disease Reply. ANN NEUROL , 65 (4) 481 - 481. 10.1002/ana.21690.

Schapira, AHV; (2009) Disease modifying agents in Parkinson's disease? In: JOURNAL OF THE NEUROLOGICAL SCIENCES. (pp. S46 - S46). ELSEVIER SCIENCE BV

Schapira, AHV; (2009) Etiology and Pathogenesis of Parkinson Disease. NEUROL CLIN , 27 (3) 583 - +. 10.1016/j.ncl.2009.04.004.

Schapira, AHV; (2009) Molecular and clinical pathways to neuroprotection of dopaminergic drugs in Parkinson disease. NEUROLOGY , 72 S44 - S50.

Schapira, AHV; (2009) Neurobiology and treatment of Parkinson's disease. TRENDS PHARMACOL SCI , 30 (1) 41 - 47. 10.1016/j.tips.2008.10.005.

Schapira, AHV; Emre, M; Jenner, P; Poewe, W; (2009) Levodopa in the treatment of Parkinson's disease. EUR J NEUROL , 16 (9) 982 - 989. 10.1111/j.1468-1331.2009.02697.x.

Taanman, JW; Daras, M; Albrecht, J; Davie, CA; Mallam, EA; Muddle, JR; ... Ginsberg, L; + view all (2009) Characterization of a novel TYMP splice site mutation associated with mitochondrial neurogastrointestinal encephalomyopathy (MNGIE). NEUROMUSCULAR DISORD , 19 (2) 151 - 154. 10.1016/j.nmd.2008.11.002.

Taanman, JW; Rahman, S; Pagnamenta, AT; Morris, AAM; Bitner-Glindzicz, M; Wolf, NI; ... Schapira, AHV; + view all (2009) Analysis of Mutant DNA Polymerase gamma in Patients With Mitochondrial DNA Depletion. HUM MUTAT , 30 (2) 248 - 254. 10.1002/humu.20852.

Tolosa, E; Chaudhuri, KR; Schapira, A; Poewe, W; (2009) Non-Motor Symptoms of Parkinson's Disease. Oxford Univ Pr

Warner, TT; (2009) The genetics and pathogenesis of dystonia. In: Schapira, AHV and Lang, AE and Fahn, S, (eds.) Movement Disorders 4. (457 - 473). Elsevier: Philadelphia.

Webb, T; Mead, S; Beck, J; Uphill, J; Pal, S; Hampson, S; ... Collinge, J; + view all (2009) Seven-year discordance in age at onset in monozygotic twins with inherited prion disease (P102L). NEUROPATH APPL NEURO , 35 (4) 427 - 432. 10.1111/j.1365-2990.2009.01012.x.

2008

Barone, P; Schapira, AHV; Debieuvre, CD; Massey, D; (2008) Design of a randomized, placebo-controlled trial of pramipexole in patients with Parkinson's disease and depressive symptoms. In: MOVEMENT DISORDERS. (pp. S199 - S199). WILEY-LISS

Bet, L; Bareggi, SR; Pacei, F; Bondiolotti, G; Meola, G; Schapira, AHV; (2008) Bimodal administration of entacapone in Parkinson's disease patients improves motor control. EUR J NEUROL , 15 (3) 268 - 273. 10.1111/j.1468-1331.2007.02043.x.

Cooper, JM; Korlipara, LVP; Hart, PE; Bradley, JL; Schapira, AHV; (2008) Coenzyme Q(10) and vitamin E deficiency in Friedreich's ataxia: predictor of efficacy of vitamin E and coenzyme Q(10) therapy. EUR J NEUROL , 15 (12) 1371 - 1379. 10.1111/j.1468-1331.2008.02318.x.

DiFrancesco, JC; Cooper, JM; Lam, A; Hart, PE; Tremolizzo, L; Ferrarese, C; Schapira, AH; (2008) MELAS mitochondrial DNA mutation A3243G reduces glutamate transport in cybrids cell lines. EXP NEUROL , 212 (1) 152 - 156. 10.1016/j.expneurol.2008.03.015.

Grosset, DG; Schapira, AH; (2008) Timing the initiation of treatment in Parkinson's disease. J NEUROL NEUROSUR PS , 79 (6) 615 - 615. 10.1136/jnnp.2008.144741.

Healy, DG; Falchi, M; O'Sullivan, SS; Bonifati, V; Durr, A; Bressman, S; ... Int LRRK2 Consortium,; + view all (2008) Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. LANCET NEUROL , 7 (7) 583 - 590. 10.1016/S1474-4422(08)70117-0. Gold open access

Healy, DG; Wood, NW; Schapira, AH; (2008) Test for LRRK2 mutations in patients with Parkinson's disease. Pract Neurol , 8 (6) 381 - 385. 10.1136/jnnp.2008.162420.

Martinez, C; Finnern, HW; Rietbrock, S; Eaton, S; Chaudhuri, KR; Schapira, AHV; (2008) Patterns of treatment for restless legs syndrome in primary care in the united kingdom. CLIN THER , 30 (2) 405 - 418. 10.1016/j.clinthera.2008.02.001.

Olanow, CW; Kleburtz, K; Schapira, AHV; (2008) Why Have We Failed to Achieve Neuroprotection in Parkinson's Disease? ANN NEUROL , 64 (6) S101 - S110. 10.1002/ana.21461.

Rohrer, JD; Schapira, AH; (2008) Transient Horner's syndrome during lumbar epidural anaesthesia. EUR J NEUROL , 15 (5) 530 - 531. 10.1111/j.1468-1331.2008.02120.x.

Schapira, AH; (2008) Progress in Parkinson's disease. EUR J NEUROL , 15 (1) 1 - 1. 10.1111/j.1468-1331.2007.02036.x.

Schapira, AH; Hsu, HH; Scrine, K; Gordon, MF; Marek, KL; (2008) PROUD: The impact of early vs. delayed treatment with prampiexole on new onset Parkinson's disease. In: MOVEMENT DISORDERS. (pp. S194 - S194). WILEY-LISS

Schapira, AH; Hsu, HH; Scrine, K; Gordon, MF; Marek, KL; (2008) PROUD: The impact of early vs. delayed treatment with pramipexole on new onset Parkinson's disease. In: MOVEMENT DISORDERS. (pp. S194 - S194). WILEY-LISS

Schapira, AHV; (2008) Mitochondrial Dysfunction in Neurodegenerative Diseases. NEUROCHEM RES , 33 (12) 2502 - 2509. 10.1007/s11064-008-9855-x.

Schapira, AHV; (2008) Controlling motor symptoms and fluctuations in adjunct therapy. In: EUROPEAN JOURNAL OF NEUROLOGY. (pp. 418 - 418). BLACKWELL PUBLISHING

Schapira, AHV; (2008) Rasagiline in neurodegeneration. EXP NEUROL , 212 (2) 255 - 257. 10.1016/j.expneurol.2008.05.002.

Schapira, AHV; (2008) Progress in neuroprotection in Parkinson's disease. EUR J NEUROL , 15 5 - 13.

Schapira, AHV; (2008) The scientific and clinical basis for future therapies in Parkinson's disease - Foreword. EUR J NEUROL , 15 V - V.

Schapira, AHV; (2008) The clinical relevance of levodopa toxicity in the treatment of Parkinson's disease. MOVEMENT DISORD , 23 S515 - S520. 10.1002/mds.22146.

Schapira, AHV; (2008) Mitochondria in the aetiology and pathogenesis of Parkinson's disease. LANCET NEUROL , 7 (1) 97 - 109.

Schapira, AHV; Borgohain, R; Stocchi, F; Lorenzana, P; Onofrj, M; Lucini, V; ... Study Investigators,; + view all (2008) Long-term safety and efficacy of safinamide added to dopamine agonists in early Parkinson's disease (PD). In: NEUROLOGY. (pp. A424 - A424). LIPPINCOTT WILLIAMS & WILKINS

Schapira, AHV; Hsu, HH; Scrine, K; Gordon, MF; Marek, KL; (2008) PROUD: the impact of early vs. delayed treatment with pramipexole on new onset Parkinson's disease. In: EUROPEAN JOURNAL OF NEUROLOGY. (pp. 132 - 132). BLACKWELL PUBLISHING

Schapira, AHV; Olanow, CW; (2008) Drug Selection and Timing of Initiation of Treatment in Early Parkinson's Disease. ANN NEUROL , 64 (6) S47 - S55. 10.1002/ana.21460.

Schapira, AHV; Stocchi, F; Hunter, B; Giorgi, L; (2008) Adjunctive ropinirole 24-hour prolonged release compared with adjunctive ropinirole immediate release in patients with advanced PD: results from a per-protocol analysis of the PREPARED study. In: EUROPEAN JOURNAL OF NEUROLOGY. (pp. 131 - 132). BLACKWELL PUBLISHING

Schapira, AHV; Stocchi, F; Hunter, B; Giorgi, L; (2008) Comparison of adjunctive ropinirole 24-hour prolonged release and ropinirole immediate release in patients with advanced Parkinson's disease: A per-protocol analysis of the PREPARED study. In: MOVEMENT DISORDERS. (pp. S196 - S197). WILEY-LISS

Stocchi, F; Hunter, B; Giorgi, L; Schapira, AHV; (2008) Adjunctive ropinirole 24-hour prolonged release compared with ropinirole immediate release in patients with advanced Parkinson's disease (PD): the PREPARED study. In: EUROPEAN JOURNAL OF NEUROLOGY. (pp. 134 - 134). BLACKWELL PUBLISHING

Stocchi, F; Hunter, B; Giorgi, L; Schapira, AHV; (2008) On evaluation of symptom control in patients with advanced PD receiving adjunctive ropinirole 24-hour prolonged release versus ropinirole immediate release: results from the PREPARED study. In: EUROPEAN JOURNAL OF NEUROLOGY. (pp. 134 - 134). BLACKWELL PUBLISHING

Stocchi, F; Huter, B; Giorgi, L; Schapira, AHV; (2008) Comparison of adjunctive ropinirole 24-hour prolonged release and ropinirole immediate release in patients with advanced Parkinson's disease: The PREPARED study. In: MOVEMENT DISORDERS. (pp. S215 - S216). WILEY-LISS

Tan, EK; Schapira, AH; (2008) Hunting for genes in essential tremor. EUR J NEUROL , 15 (9) 889 - 890. 10.1111/j.1468-1331.2008.02226.x.

Tan, EK; Schapira, AH; (2008) Uniting Chinese across Asia: The LRRK2 Gly2385Arg risk variant. EUR J NEUROL , 15 (3) 203 - 204. 10.1111/j.1468-1331.2007.02053.x.

Yamamoto, M; Schapira, AH; (2008) Dopamine agonists in Parkinson's disease. Expert Rev Neurother , 8 (4) 671 - 677. 10.1586/14737175.8.4.671.

2007

Schapira, AHV and Byrne, E and Dimauro, S and Frackowiak, RSJ and Johnson, RT and Mizuno, Y and Samuels, MA and Silberstein, SD and Wszolek, ZK (Eds). (2007) Neurology and clinical neuroscience - a textbook of neurology. Elsevier: Philadelphia.

Anand, R; Onofrj, M; Schapira, AH; Rossetti, SM; (2007) Safinamide potentiates the effects of DA-agonists in early stage Parkinson's disease (PD) patients. In: MOVEMENT DISORDERS. (pp. S244 - S244). WILEY-LISS

Barone, P; Goetz, CG; Houben, J; Juergen, K; Leentjens, AFG; Poewe, W; ... Tolosa, E; + view all (2007) PRODEST study: depressive symptoms in Parkinson's disease. In: MOVEMENT DISORDERS. (pp. S183 - S183). WILEY-LISS

Barone, P; Goetz, CG; Houben, JJ; Koester, J; Leentjens, AF; Poewe, W; ... Tolosa, E; + view all (2007) Prodest - Depressive symptoms in Parkinson's disease: Demographic data. In: EUROPEAN JOURNAL OF NEUROLOGY. (pp. 61 - 61). BLACKWELL PUBLISHING

Barone, P; Goetz, CG; Houben, JJ; Koster, J; Leentjens, AFG; Powe, W; ... Tolosa, E; + view all (2007) PRODEST - Depressive symptoms in Parkinson's disease: Pattern across scales. PARKINSONISM RELAT D , 13 S51 - S51.

Chaudhuri, KR; Martinez-Martin, P; Brown, RG; Sethi, K; Stocchi, F; Odin, P; ... Schapira, AHV; + view all (2007) The metric properties of a novel non-motor symptoms scale for Parkinson's disease: Results from an international pilot study. MOVEMENT DISORD , 22 (13) 1901 - 1911. 10.1002/mds.21596.

Chaudhuri, KR; Martinez-Martin, P; Schapira, AHV; Stocchi, F; Sethi, K; Odin, P; ... PDNMG,; + view all (2007) International validation of the first non-motor questionnaire (NMSQuest) and scale (NMSS) for Parkinson's disease. In: JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY. (pp. 213 - 213). B M J PUBLISHING GROUP

Cooper, JM; Schapira, AHV; (2007) Friedreich's ataxia: Coenzyme Q(10) and vitamin E therapy. MITOCHONDRION , 7 S127 - S135. 10.1016/j.mito.2007.04.001.

Giladi, N; Boroojerdi, B; Korczyn, AD; Burn, DJ; Clarke, CE; Schapira, AH; SP513 Investigators,; (2007) Rotigotine transdermal patch in early Parkinson's disease: A randomized, double-blind, controlled study versus placebo and ropinirole. MOVEMENT DISORD , 22 (16) 2398 - 2404. 10.1002/mds.21741.

Ginsberg, L; Daras, M; Davie, C; Albrecht, J; Schapira, AHV; Weatherall, M; Taanman, JW; (2007) A novel MNGIE mutation. In: EUROPEAN JOURNAL OF NEUROLOGY. (pp. 238 - 238). BLACKWELL PUBLISHING

Ginsberg, L; Schapiro, AHV; Taanman, JM; (2007) Relapsing neuropathy in an 18-year-old woman. LANCET NEUROL , 6 (2) 192 - 198.

Lynch, JM; Sisodiya, SM; (2007) Genetics of epilepsy. In: Schapira, AHV, (ed.) Neurology and clinical neuroscience. (681 - 689). Mosby/Elsevier: Philadelphia. Green open access
file

Martinez-Martin, P; Schapira, AHV; Stocchi, F; Sethi, K; Odin, P; MacPhee, G; ... Chaudhuri, KR; + view all (2007) Prevalence of nonmotor symptoms in Parkinson's disease in an international setting; Study using nonmotor symptoms questionnaire in 545 patients. MOVEMENT DISORD , 22 (11) 1623 - 1629. 10.1002/mds.21586.

Pienaar, I; Carr, J; Hattingh, S; Morten, K; Schallert, T; Schapira, AH; Daniels, W; (2007) A proteomics and behavioral analysis of the interaction of statins with mitochondrial proteins in a rat model of Parkinson's disease. PARKINSONISM RELAT D , 13 S91 - S91.

Pienaar, I; Carr, J; Hattingh, S; Morten, K; Schallert, T; Schapira, AH; Daniels, W; (2007) A proteomics and behavioral analysis of the interaction of statins with mitochondrial proteins in a rat model of Parkinson's disease. PARKINSONISM RELAT D , 13 S133 - S133.

Schapira, AH; (2007) Mitochondria in the etiology of Parkinson's disease. Handb Clin Neurol , 83 479 - 491. 10.1016/S0072-9752(07)83022-3.

Schapira, AHV; (2007) Ropinirole 24-hour extended release for Parkinson's disease. In: AKTUELLE NEUROLOGIE. (pp. S15 - S17). GEORG THIEME VERLAG KG

Schapira, AHV; (2007) Treatment options in the modern management of Parkinson Disease. ARCH NEUROL-CHICAGO , 64 (8) 1083 - 1088.

Schapira, AHV; (2007) Mitochondrial dysfunction in Parkinson's disease. CELL DEATH DIFFER , 14 (7) 1261 - 1266. 10.1038/sj.cdd.4402160.

Schapira, AHV; (2007) Future directions in the treatment of Parkinson's disease. MOVEMENT DISORDERS , 22 S385 - S391. 10.1002/mds.21679.

Schapira, AHV; (2007) Metabolic causes of ataxia. In: Brice, A and Pulst, SM, (eds.) Spinocerebellar degenerations: the ataxias and spastic paraplegias. (255 - 267). Butterworth-Heinemann Elsevier: Philadelphia.

Schapira, AHV; (2007) Mitochondria in Movement Disorders. In: Jankovic, J and Tolosa, E, (eds.) Parkinson's Disease & Movement Disorders. (284 - 297). Lippincott Williams & Wilkins: Philadelphia.

Schapira, AHV; (2007) Mitochondria in the etiology of Parkinson's disease. In: Koller, WC and Melamed, E, (eds.) Parkinson's disease and related disorders, part I. (481 - 491). Elsevier: Edinburgh.

Schapira, AHV; Chau, KY; Cooper, JM; (2007) Cabergoline protects against paraquant and alpha-synuclein mutation toxicity. In: NEUROLOGY. (pp. A110 - A110). LIPPINCOTT WILLIAMS & WILKINS

Sharma, T; Stocchi, F; Schapira, AH; Borgohain, R; LoreDzana, P; Onoftj, M; ... 015 Study Grp,; + view all (2007) Satinamide treatment improves cognition in Parkinson's disease. In: MOVEMENT DISORDERS. (pp. XII - XIII). WILEY-LISS

Simonson, W; Hauser, RA; Schapira, AHV; (2007) Role of the pharmacist in the effective management of wearing-off in Parkinson's disease. ANN PHARMACOTHER , 41 (11) 1842 - 1849. 10.1345/aph.1K348.

Turner, C; Cooper, JM; Schapira, AHV; (2007) Clinical correlates of mitochondrial function in Huntington's disease muscle. MOVEMENT DISORD , 22 (12) 1715 - 1721. 10.1002/mds.21540.

Warner, TT; (2007) Dystonia. In: Schapira, AHV, (ed.) Neurology and Clinical Neurosciences. (443 - 454). Mosby Elsevier: Philadelphia.

2006

Cano, SJ; Hobart, JC; Hart, PE; Kolipara, LVP; Schapira, AHV; Cooper, JM; (2006) International co-operative ataxia rating scale (ICARS): Suitable for clinical practice and treatment trials in Friedreich's ataxia? In: JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY. (pp. 133 - 133). B M J PUBLISHING GROUP

Cano, SJ; Riazi, A; Cooper, JM; Schapira, AHV; Hobart, JC; (2006) The Friedreich's Ataxia impact scale (FAIS) meets the needs of today's clinical studies. In: JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY. (pp. 133 - 133). B M J PUBLISHING GROUP

Chaudhuri, KR; Healy, DG; Schapira, AHV; (2006) Non-motor symptoms of Parkinson's disease: diagnosis and management. LANCET NEUROL , 5 (3) 235 - 245.

Chaudhuri, KR; Martinez-Martin, P; Schapira, AHV; Sethi, K; Ondo, W; Stocchi, F; ... Brown, R; + view all (2006) International validation of the first united non motor symptoms scale for Parkinson's disease. Results from the first pilot NMSS study. In: NEUROLOGY. (pp. A124 - A124). LIPPINCOTT WILLIAMS & WILKINS

Chaudhuri, KR; Martinez-Martin, P; Schapira, AHV; Stocchi, F; Sethi, K; Odin, P; ... Olanow, CW; + view all (2006) International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson's disease: The NMSQuest study. MOVEMENT DISORD , 21 (7) 916 - 923. 10.1002/mds.20844.

Iravani, MM; Haddon, CO; Cooper, JM; Jenner, P; Schapira, AH; (2006) Pramipexole protects against MPTP toxicity in non-human primates. J NEUROCHEM , 96 (5) 1315 - 1321. 10.1111/j.1471-4159.2005.03625.x.

Lodi, R; Tonon, C; Calabrese, V; Schapira, AHV; (2006) Friedreich's ataxia: From disease mechanisms to therapeutic interventions. ANTIOXID REDOX SIGN , 8 (3-4) 438 - 443.

Naidu, Y; Schapira, AH; Martinez-Martin, P; Sethi, K; Odin, P; Stocchi, F; ... Chaudhuri, KR; + view all (2006) International validation study of the first comprehensive unified Nonmotor Symptoms Scale (NMSS) for Parkinson's disease (PD). In: MOVEMENT DISORDERS. (pp. S613 - S613). WILEY-LISS

Olanow, CW; Schapira, AHV; LeWitt, PA; Kieburtz, K; Sauer, D; Olivieri, G; ... Hubble, J; + view all (2006) TCH346 as a neuroprotective drug in Parkinson"s disease: a double-blind, randomised, controlled trial. LANCET NEUROL , 5 (12) 1013 - 1020. 10.1016/S1474-4422(06)70602-0.

Riazi, A; Cano, SJ; Cooper, JM; Bradley, JL; Schapira, AHV; Hobart, JC; (2006) Coordinating outcomes measurement in ataxia research: Do some widely used generic rating scales tick the boxes? MOVEMENT DISORD , 21 (9) 1396 - 1403. 10.1002/mds.20985.

Schapira, A.H.V.; Cleeter, M.W.J.; Muddle, J.R.; Workman, J.M.; Cooper, J.M.; King, R.H.M.; (2006) Proteasomal inhibition causes loss of nigral tyrosine hydroxylase neurons. Annals of Neurology , 60 (2) pp. 253-255. 10.1002/ana.20934.

Schapira, AH; (2006) Scientific basis for neuroprotection in Parkinson's disease. In: MOVEMENT DISORDERS. (pp. S14 - S14). WILEY-LISS

Schapira, AH; (2006) The use of rasagiline in Parkinson's disease. journal of neural transmission , 71 1 - 5.

Schapira, AHV; (2006) Parkinson's disease. In: Schapira, AHV, (ed.) Neurology and clinical neuroscience. (927 - 960). Mosby/Elsevier: Philadelphia.

Schapira, AHV; (2006) Sudden onset of sleep and daytime drowsiness in Parkinson's disease. In: JOURNAL OF THE NEUROLOGICAL SCIENCES. (pp. 319 - 319). ELSEVIER SCIENCE BV

Schapira, AHV; (2006) Restless Legs Syndrome - Preface. EUR J NEUROL , 13 1 - 1.

Schapira, AHV; (2006) RLS patients: who are they? EUR J NEUROL , 13 2 - 7.

Schapira, AHV; (2006) Improving the management of Parkinson's disease: New ropinirole data from EASE-PD in context. EUR J NEUROL , 13 317 - 317.

Schapira, AHV; (2006) Non-motor symptoms. EUR J NEUROL , 13 316 - 317.

Schapira, AHV; (2006) The importance of LRRK2 mutations in Parkinson disease. ARCH NEUROL-CHICAGO , 63 (9) 1225 - 1228.

Schapira, AHV; (2006) Mitochondrial disease. LANCET , 368 (9529) 70 - 82.

Schapira, AHV; (2006) Mitochondria in neurodegeneratives diseases. In: INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY. (pp. S82 - S83). CAMBRIDGE UNIV PRESS

Schapira, AHV; (2006) Etiology of Parkinson's disease. NEUROLOGY , 66 (10) S10 - S23.

Schapira, AHV; (2006) The use of rasagiline in Parkinson's disease. J NEURAL TRANSM-SUPP (71) 157 - 161.

Schapira, AHV; Bezard, E; Brotchie, J; Calon, F; Collingridge, GL; Ferger, B; ... Davidai, G; + view all (2006) Novel pharmacological targets for the treatment of Parkinson's disease. NAT REV DRUG DISCOV , 5 (10) 845 - 854. 10.1038/nrd2087.

Schapira, AHV; Cleeter, MWJ; Muddle, JR; Workman, JM; Cooper, JM; King, RHM; (2006) Proteasomal inhibition causes loss of nigral tyrosine hydroxylase neurons. ANN NEUROL , 60 (2) 253 - 255. 10.1002/ana.20934.

Schapira, AHV; Muddle, JR; Workman, JM; Cleeter, MWJ; Cooper, MJ; King, RHM; (2006) Systemic proteasomal inhibition causes loss of nigral TH positive neurons. In: NEUROLOGY. (pp. A146 - A146). LIPPINCOTT WILLIAMS & WILKINS

Schapira, AHV; Obeso, J; (2006) Timing of treatment initiation in Parkinson's disease: A need for reappraisal? ANN NEUROL , 59 (3) 559 - 562.

Schapira, AHV; Obeso, JA; (2006) Treatment should not be initiated too soon in Parkinson's disease - Reply. ANN NEUROL , 59 (3) 564 - 565.

Stacey, M; Hauser, R; Oertel, W; Schapira, AH; Sethi, K; Stocchi, F; Tolosa, E; (2006) End of dose wearing off in Parkinson's disease; A 9-question survey assessment. Clinical Pharmacology , 29 (6) 312 - 321.

Stacy, M; Hauser, R; Oertel, W; Schapira, A; Sethi, K; Stocchi, F; Tolosa, E; (2006) End-of-dose wearing off in Parkinson disease: a 9-question survey assessment. Clin Neuropharmacol , 29 (6) 312 - 321. 10.1097/01.WNF.0000232277.68501.08.

Tsuboi, Y; Yamada, T; Chaudhuri, RK; Martinez-Martin, P; Schapira, AH; P International,; (2006) Comparison of profile of non motor symptoms in Japanese patients with PD with Euoprean patients and healthy controls. Extension of the NMSQuest study. In: MOVEMENT DISORDERS. (pp. S648 - S649). WILEY-LISS

2005

Baracca, A; Solaini, G; Sgarbi, G; Lenaz, G; Baruzzi, A; Schapira, AHV; ... Carelli, V; + view all (2005) Severe impairment of complex I-Driven adenosine triphosphate synthesis in Leber hereditary optic neuropathy cybrids. ARCH NEUROL-CHICAGO , 62 (5) 730 - 736.

Cano, SJ; Hobart, JC; Hart, PE; Korlipara, LVP; Schapira, AH; Cooper, JM; (2005) International Cooperative Ataxia Rating Scale (ICARS): Appropriate for studies of Friedreich's ataxia? MOVEMENT DISORD , 20 (12) 1585 - 1591. 10.1002/mds.20651.

Chaudhuri, KR; Martinez-Martin, P; Schapira, AHV; Ondo, W; Sethi, K; PD NMS Scale Dev Grp,; (2005) An international multicentre study validating the first screening questionnaire (NMS-quest) for comprehensive assessment of non motor symptoms of Parkinson's disease. In: MOVEMENT DISORDERS. (pp. S50 - S50). WILEY-LISS

Danielson, SR; Carelli, V; Tan, GL; Martinuzzi, A; Schapira, AHV; Savontaus, ML; Cortopassi, GA; (2005) Isolation of transcriptomal changes attributable to LHON mutations and the cybridization process. BRAIN , 128 1026 - 1037. 10.1093/brain/awh447.

Gu, M; Iravani, MM; Cooper, JM; King, D; Jenner, P; Schapira, AHV; (2005) Pramipexole protects against apoptotic cell death by non-dopaminergic mechanisms (vol 91, pg 1075, 2004). J NEUROCHEM , 92 (1) 215 - 215. 10.1111/j.1471-4159.2004.02966.x.

Hart, PE; Lodi, R; Rajagopalan, B; Bradley, JL; Crilley, JG; Turner, C; ... Cooper, JM; + view all (2005) Antioxidant treatment of patients with Friedreich ataxia - Four-year follow-up. ARCH NEUROL-CHICAGO , 62 (4) 621 - 626.

Lo, S; Tolner, B; Taanman, JW; Cooper, JM; Gu, M; Hartley, JA; ... Hochhauser, D; + view all (2005) Assessment of the significance of mitochondrial DNA damage by chemotherapeutic agents. INT J ONCOL , 27 (2) 337 - 344.

Schapira, A; Bate, G; Kirkpatrick, P; (2005) Rasagiline. Nat Rev Drug Discov , 4 (8) 625 - 626. 10.1038/nrd1803.

Schapira, AH; (2005) Rasagiline, a novel second generation MAO-B inhibitor - pharmacological profile. EUR J NEUROL , 12 329 - 329.

Schapira, AH; (2005) Mitochondrial DNA and disease: what happens when things go wrong? The Biochemist , 27 (3) 24 - 27.

Schapira, AHV; (2005) Present and future drug treatment for Parkinson's disease. J NEUROL NEUROSUR PS , 76 (11) 1472 - 1478. 10.1136/jnnp.2004.035980. Gold open access

Schapira, AHV; Olanow, CW; (2005) Principles of treatment in Parkinson's disease. Butterworth-Heinemann

Strand, AD; Aragaki, AK; Shaw, D; Bird, T; Holton, J; Turner, C; ... Olson, JM; + view all (2005) Gene expression in Huntington's disease skeletal muscle: a potential biomarker. HUM MOL GENET , 14 (13) 1863 - 1876. 10.1093/hmg/ddi192.

Taanman, JW; Schapira, AHV; (2005) Analysis of the trinucleotide CAG repeat from the DNA polymerase gamma gene (POLG) in patients with Parkinson's disease. NEUROSCI LETT , 376 (1) 56 - 59. 10.1016/j.neulet.2004.11.023.

Tabrizi, SJ; Blamire, AM; Manners, DN; Rajagopalan, B; Styles, P; Schapira, AHV; Warner, TT; (2005) High-dose creatine therapy for Huntington disease: A 2-year clinical and MRS study. NEUROLOGY , 64 (9) 1655 - 1656.

2004

Beretta, S; Mattavelli, L; Sala, G; Tremolizzo, L; Schapira, AHV; Martinuzzi, A; ... Ferrarese, C; + view all (2004) Leber hereditary optic neuropathy mtDNA mutations disrupt glutamate transport in cybrid cell lines. BRAIN , 127 2183 - 2192. 10.1093/brain/awh258.

Bradley, J.L.; Homayoun, S.; Hart, P.E.; Schapira, A.H.V.; Cooper, J.M.; (2004) Role of oxidative damage in Friedreich's Ataxia. Neurochemical Research , 29 (3) pp. 561-567. 10.1023/B:NERE.0000014826.00881.c3.

Bradley, JL; Homayoun, S; Hart, PE; Schapira, AHV; Cooper, JM; (2004) Role of oxidative damage in Friedreich's ataxia. NEUROCHEM RES , 29 (3) 561 - 567.

Chaudhuri, K; Schapira, AH; Martinez-Martin, P; Brown, K; (2004) On behalf of the International Parkinson's Disese Non-Motor Symptom Scale Development Group. Can we improve the holistic assessment of Parkinson's disease? The development of a non-motor symptom questionnaire adn scale for PD:. Advances in Clinical Neuroscience and Rehabilitation , 4 20 - 21.

Chaudhuri, KR; Forbes, A; Grosset, D; Lees, A; Shneerson, J; Schapira, A; ... Williams, A; + view all (2004) Diagnosing restless legs syndrome (RLS) in primary care. CURR MED RES OPIN , 20 (11) 1785 - 1795. 10.1185/030079904X5472.

Chaudhuri, KR; Schapira, AHV; Martinez-Martin, P; Sethi, K; MacPhee, G; Brown, R; ... International Nonmotor Symptom,; + view all (2004) Development and pilot study of the first nonmotor symptom screening questionnaire and scale for Parkinson's disease using an international multidisciplinary approach. In: MOVEMENT DISORDERS. (pp. 1120 - 1120). WILEY-LISS

Davie, CA; Schapira, AH; (2004) Use of COMT inhibitors in the treatment of Parkinson's disease. Clinical Geriatrics , 12 (6) 19 - 24.

Francis, J; Cooke, F; Bradley, JL; Blamire, AM; Schapira, AHV; Neubauer, S; ... Rajagopalan, B; + view all (2004) Myocardial. hypertrophy in Friedreich's ataxia (FA) is a function of duration of the disease and the length of the GAA trinucleotide repeat; A cross sectional MRI study. In: HEART. (pp. A58 - A58). B M J PUBLISHING GROUP

Gu, M; Irvani, M; Cooper, JM; King, D; Jenner, P; Schapira, AHV; (2004) Pramipexole protects against apoptotic cell death by non-dopaminergic mechanisms. J NEUROCHEM , 91 (5) 1075 - 1081. 10.1111/j.1471-4159.2004.02804.x.

Korlipara, LVP; Cooper, JM; Schapira, AHV; (2004) Oxidative stress in a neuronal model of alpha synuclein overexpression. In: JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY. (pp. 1226 - 1226). B M J PUBLISHING GROUP

Korlipara, LVP; Cooper, JM; Schapira, AHV; (2004) Differences in toxicity of the catechol-O-methyl transferase inhibitors, tolcapone and entacapone to cultured human neuroblastoma cells. NEUROPHARMACOLOGY , 46 (4) 562 - 569. 10.1016/j.neuropharm.2003.10.015.

MacMahon, D; Koller, W; Martinex-Martin, P; Chaudhuri, K; Schapira, A; Sethi, K; Brown, R; (2004) Can we improve the holistic assessment of Parkinson's disease? The development of a non-motor symptom questionnaire and scale for Parkinson's disease. Advances in Clinical Opinions , 20 1785 - 1795.

McCabe, DJH; Turner, NC; Chao, D; Leff, A; Gregson, NA; Womersley, HJ; ... Schapira, AHV; + view all (2004) Paraneoplastic "stiff person syndrome" with metastatic adenocarcinoma and anti-Ri antibodies. NEUROLOGY , 62 (8) 1402 - 1404.

Olanow, CW; Schapira, AHV; (2004) Measuring the effects of therapy in Parkinson disease - Reply. JAMA-J AM MED ASSOC , 291 (20) 2431 - 2431.

Orth, M; Tabrizi, SJ; Tomlinson, C; Messmer, K; Korlipara, LVP; Scapira, AHV; Cooper, JM; (2004) G209A mutant alpha synuclein expression specifically enhances dopamine induced oxidative damage. NEUROCHEM INT , 45 (5) 669 - 676. 10.1016/j.neuint.2004.03.029.

Page, RA; Davie, CA; MacManus, D; Miszkiel, KA; Walshe, JM; Miller, DH; ... Schapira, AHV; + view all (2004) Clinical correlation of brain MRI and MRS abnormalities in patients with Wilson disease. NEUROLOGY , 63 (4) 638 - 643.

Rafique, R; Schapira, AHV; Cooper, JM; (2004) Mitochondrial respiratory chain dysfunction in ageing; Influence of vitamin E deficiency. FREE RADICAL RES , 38 (2) 157 - 165. 10.1080/10715760310001643311.

Samii, A; Nutt, JG; Ransom, BR; (2004) Parkinson's disease. (Vol.363).

Schapira, A; (2004) Understanding Parkinson's Disease. Pool: Family Doctor Association. British Medical Association: London.

Schapira, A; Lodi, R; (2004) Assessment of in vitro and in vivo mitochondrial function in Friedreich's ataxia and Huntington's disease. Methods Mol Biol , 277 293 - 307. 10.1385/1-59259-804-8:293.

Schapira, AH; (2004) Excessive daytime sleepiness in Parkinson's disease. NEUROLOGY , 63 (8) S24 - S27.

Schapira, AH; (2004) Disease modification in Parkinson's disease. Lancet Neurol , 3 (6) 362 - 368. 10.1016/S1474-4422(04)00769-0.

Schapira, AH; (2004) Disease of muscle and the neuromuscular junction. Clinical Neurology 130 - 153.

Schapira, AHV; (2004) Disease modification in Parkinson's disease. (vol 3, pg 362, 2004). LANCET NEUROL , 3 (7) 443 - 443.

Schapira, AHV; (2004) Restless legs syndrome - An update on treatment options. DRUGS , 64 (2) 149 - 158.

Schapira, AHV; Chaudhuri, KR; Gershanik, O; Stocchi, F; (2004) Understanding the importance of the nocturnal symptoms of Parkinson's disease: Diagnosis, treatment, and quality of life. EUR J NEUROL , 11 357 - 357.

Schapira, AHV; Olanow, CW; (2004) Neuroprotection in Parkinson disease - Mysteries, myths, and misconceptions. JAMA-J AM MED ASSOC , 291 (3) 358 - 364.

Tabrizi, SJ; Blamire, AM; Rajagopalan, B; Manners, D; Schapira, AH; Warner, TT; (2004) High dose creatine therapy for Huntington's disease: Clinical and 31 phosphorous magnetic resonance spectroscopy ((31P) MRS) findings in a 2-year study. In: MOVEMENT DISORDERS. (pp. S51 - S51). WILEY-LISS

Wilkinson, PA; Crosby, AH; Turner, C; Bradley, LJ; Ginsberg, L; Wood, NW; ... Warner, TT; + view all (2004) A clinical, genetic and biochemical study of SPG7 mutations in hereditary spastic paraplegia. BRAIN , 127 973 - 980. 10.1093/brain/awh125.

2003

Cooper, JM; Schapira, AHV; (2003) Friedreich's Ataxia: Disease mechanisms, antioxidant and coenzyme Q(10) therapy. BIOFACTORS , 18 (1-4) 163 - 171.

Cortopassi, G; Tong, W; Wong, A; Carelli, V; Martinuzzi, A; Schapira, AHV; Danielson, SR; (2003) Mitochondrial fusion and Leber's hereditary optic neuropathy mtDNA point mutations cause altered nuclear gene expression. In: INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE. (pp. U395 - U395). ASSOC RESEARCH VISION OPHTHALMOLOGY INC

Ghelli, A; Zanna, C; Porcelli, AM; Schapira, AH; Martinuzzi, A; Carelli, V; Rugolo, M; (2003) Leber's hereditary optic neuropathy (LHON) pathogenic mutations induce mitochondrial-dependent apoptotic death in transmitochondrial cells incubated with galactose medium. Journal of Biological Chemistry , 278 (6) 4146 - 4150. Gold open access

Ghelli, A; Zanna, C; Porcelli, AM; Schapira, AHV; Martinuzzi, A; Carelli, V; Rugolo, M; (2003) Leber's hereditary optic neuropathy (LHON) pathogenic mutations induce mitochondrial-dependent apoptotic death in transmitochondrial cells incubated with galactose medium. J BIOL CHEM , 278 (6) 4145 - 4150. 10.1074/jbc.M210285200. Gold open access

Lodi, R; Rajagopalan, B; Schapira, AHV; Cooper, JM; (2003) Cardiac bioenergetics in Friedreich's ataxia. ANN NEUROL , 54 (4) 552 - 552. 10.1002/ana.10744.

Lodi, R; Rajagopalan, B; Schapira, AHV; Hart, P; Crilley, JG; Bradley, JL; ... Cooper, JM; + view all (2003) Coenzyme Q10 and vitamin E treatment in patients with Friedreich ataxia improves cardiac bioenergetics and mechnical function. A 4 year clinical and 31 P-magnetic resonance spectroscopy study. In: HEART. (pp. A43 - A43). B M J PUBLISHING GROUP

Miller, RF; Shahmanesh, M; Hanna, MG; Unwin, RJ; Schapira, AHV; Weller, IVD; (2003) Polyphenotypic expression of mitochondrial toxicity caused by nucleoside reverse transcriptase inhibitors. ANTIVIR THER , 8 (3) 253 - 257.

Olanow, CW; Schapira, AHV; Agid, Y; (2003) Neuroprotection for Parkinson's disease: Prospects and promises. ANN NEUROL , 53 S1 - S2.

Orth, M; Cooper, JM; Bates, GP; Schapira, AHV; (2003) Inclusion formation in Huntington's disease R6/2 mouse muscle cultures. J NEUROCHEM , 87 (1) 1 - 6. 10.1046/j.1471-4159.2003.02009.x.

Orth, M; Tabrizi, SJ; Schapira, AHV; Cooper, JM; (2003) alpha-Synuclein expression in HEK293 cells enhances the mitochondrial sensitivity to rotenone. NEUROSCI LETT , 351 (1) 29 - 32. 10.1016/S0304-3940(03)00941-8.

Schapira, AHV; (2003) Disease-modifying strategies and challenges in PD - Interactive breakout sessions. NEUROLOGY , 61 (6) S56 - S63.

Schapira, AHV; (2003) Neuroprotection in PD - A role for dopamine agonists? NEUROLOGY , 61 (6) S34 - S42.

Schapira, AHV; (2003) Progress in Parkinson's disease. NEUROLOGY , 61 (6) S1 - S3.

Schapira, AHV; (2003) Diseases of muscle and the neuromuscular junction. In: Fowler, TJ and Scadding, JW, (eds.) Clinical neurology. (130 - 153). Arnold: London.

Schapira, AHV; Gu, M; Cooper, JM; (2003) Dopamine agonist mediated neuroprotection: Mechanisms of action. In: JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY. (pp. 1179 - 1179). BRITISH MED JOURNAL PUBL GROUP

Schapira, AHV; Olanow, CW; (2003) Rationale for the use of dopamine agonists as neuroprotective agents in Parkinson's disease. ANN NEUROL , 53 S149 - S157. 10.1002/ana.10514.

Tabrizi, SJ; Blamire, AM; Manners, DN; Rajagopalan, B; Styles, P; Schapira, AHV; Warner, TT; (2003) Creatine therapy for Huntington's disease: Clinical and MRS findings in a 1-year pilot study. NEUROLOGY , 61 (1) 141 - 142.

Turner, C; Schapira, AHV; (2003) Energy metabolism and Huntington's disease. In: Bates, G and Harper, P and Jones, L, (eds.) Huntington's disease. Oxford University Press

Warner, TT; Schapira, AHV; (2003) Genetic and environmental factors in the cause of Parkinson's disease. ANN NEUROL , 53 S16 - S23. 10.1002/ana.10487.

Wilkinson, PA; Crosby, AH; Turner, C; Patel, H; Wood, NW; Schapira, AH; Warner, TT; (2003) A clinical and genetic study of SPG5A linked autosomal recessive hereditary spastic paraplegia. NEUROLOGY , 61 (2) 235 - 238.

2002

Bentley, PI; Kimber, T; Schapira, AHV; (2002) Painful third nerve palsy in MS. NEUROLOGY , 58 (10) 1532 - 1532.

Bradley, JL; Hart, PE; Al Khayatt, M; Schapira, AH; Cooper, J; (2002) Validation and use of assessment protocols to determine clinical progression in Friedreich's ataxia. In: MOVEMENT DISORDERS. (pp. S315 - S315). WILEY-LISS

Bradley, JL; Schapira, AH; Cooper, JM; (2002) Therapies for Friedreich's ataxia. EuroAtaxia Newsletter , 22 8 - 11.

Cock, HR; Schapira, AHV; (2002) A comparison of lorazepam and diazepam as initial therapy in convulsive status epilepticus. QJM-INT J MED , 95 (4) 225 - 231.

Cock, HR; Tong, X; Hargreaves, IP; Heales, SJR; Clark, JB; Patsalos, PN; ... Walker, MC; + view all (2002) Mitochondrial dysfunction associated with neuronal death following status epilepticus in rat. EPILEPSY RES , 48 (3) 157 - 168.

Danielson, SR; Wong, A; Carelli, V; Martinuzzi, A; Schapira, AHV; Cortopassi, GA; (2002) Cells bearing mutations causing Leber's hereditary optic neuropathy are sensitized to Fas-induced apoptosis. J BIOL CHEM , 277 (8) 5810 - 5815. 10.1074/jbc.M110119200. Gold open access

Davie, CA; Schapira, AHV; (2002) Wilson disease. In: UNSPECIFIED (175 - 190). ACADEMIC PRESS INC

DiMauro, S; Schapira, AHV; (2002) Mitochondrial encephalomyopathies. In: Asbury, AK and McKhann, GM and McDonald, WI and Goadsby, PJ and McArthur, JC, (eds.) Diseases of the nervous system: clinical neuroscience and therapeutic principles. (1922 - 1936). Cambridge University Press: Cambridge.

Hart, PE; De Vivo, DC; Schapira, AH; (2002) Clinical features of the mitochondrial encephalomyopathies. In: Schapira, AH and DiMauro, S, (eds.) Mitochondrial Disorders in Neurology. (35 - 68). Butterworth Heinemann: Massachusetts.

Korlipara, LP; Messmer, K; Cooper, JM; Schapira, AHV; (2002) Overexpression of wild-type and mutant alpha-synuclein in a neuroblastoma cell line. In: MOVEMENT DISORDERS. (pp. S61 - S61). WILEY-LISS

Korlipara, LV; Schapira, AH; (2002) Parkinson's disease. In: UNSPECIFIED (283 - 314).

Korlipara, LVP; Burn, DJ; Schapira, AHV; (2002) Juvenile-onset parkinsonism in a patient with Chediak-Higashi syndrome: A case report. In: MOVEMENT DISORDERS. (pp. S254 - S254). WILEY-LISS

Korlipara, LVP; Schapira, AH; (2002) Possible Mechanisms Underlying the Protective Action of Immunosuppressants Against Parkinson's Disease. The Mitochondrial Permeability Transition Pore Hypothesis. In: Borlongan, CV and Isacson, O and Sanberg, PR, (eds.) Immunosuppressant Analogs in Neuroprotection. (105 - 137). Humana Press: Totowa, New Jersey.

Korlipara, LVP; Schapira, AHV; (2002) Neuroprotection in Parkinson's disease. MAPPING THE PROGRESS OF ALZHEIMER'S AND PARKINSON'S DISEASE , 51 373 - 378.

Korlipara, LVP; Schapira, AHV; (2002) Parkinson's disease. INT REV NEUROBIOL , 53 283 - 314.

Lodi, R; Rajagopalan, B; Bradley, JL; Taylor, DJ; Crilley, JG; Hart, PE; ... Cooper, JM; + view all (2002) Mitochondrial dysfunction in Friedreich's ataxia: From pathogenesis to treatment perspectives. FREE RADICAL RESEARCH , 36 (4) 461 - 466. 10.1080/10715760290021324.

Lodi, R; Rajagopalan, B; Crilley, JG; Cooper, JM; Styles, P; Schapira, AHV; (2002) Cardiac hypertrophy in Friedreich's ataxia - Reply to letter to the editor. CARDIOVASC RES , 54 (3) 695 - 696.

Orrell, R; Schapira, AH; (2002) Mitochondria and amyotrophic lateral sclerosis. International Review of Neurobiology , 53 411 - 424.

Orrell, RW; Schapira, AHV; (2002) Mitochondria and amyotrophic lateral sclerosis. In: UNSPECIFIED (411 - 426). ACADEMIC PRESS INC

Orth, M; Schapira, AHV; (2002) Mitochondrial involvement in Parkinson's disease. NEUROCHEM INT , 40 (6) 533 - 541.

Schapira, AH; (2002) Mitochondrial Function and Dysfunction. International Review of Neurobiology: Vol.53. Academic Press

Schapira, AH; DiMauro, S; (2002) Mitochondrial Disorders in Neurology. (2nd ed.). Butterworth Heinemann: Massachusetts.

Schapira, AHV; (2002) Dopamine agonists and neuroprotection in Parkinson's diseae. EUR J NEUROL , 9 7 - 14.

Schapira, AHV; (2002) Primary and secondary defects of the mitochondrial respiratory chain. JOURNAL OF INHERITED METABOLIC DISEASE , 25 (3) 207 - 214.

Schapira, AHV; (2002) Neuroprotection and dopamine agonists. NEUROLOGY , 58 (4) S9 - S18.

Schapira, AHV; (2002) The "new" mitochondrial disorders. J NEUROL NEUROSUR PS , 72 (2) 144 - 149.

Schapira, AHV; Gu, M; King, DF; Cooper, JM; Jenner, P; (2002) Pramipexole protects against rotenone toxicity: Mechanisms and implications. NEUROLOGY , 58 (7) A495 - A495.

Spacey, SD; Valente, EM; Wali, GM; Warner, TT; Jarman, PR; Schapira, AHV; ... Wood, NW; + view all (2002) Genetic and clinical heterogeneity in paroxysmal kinesigenic dyskinesia: Evidence for a third EKD gene. MOVEMENT DISORD , 17 (4) 717 - 725. 10.1002/mds.10126.

Tabrizi, SJ; Rajagopalan, B; Styles, P; Manners, D; Schapira, AH; Warner, TT; (2002) Creatine therapy for Huntington's disease (HD): Clinical and-(31)phosphorous magnetic resonance spectroscopy (P-31 MRS) findings in a one year pilot. In: MOVEMENT DISORDERS. (pp. S319 - S319). WILEY-LISS

Tabrizi, SJ; Schapira, AHV; (2002) Mitochondrial abnormalities in neurodegenerative disorders. In: Schapira, AHV and DiMauro, S, (eds.) Mitochondrial disorders in neurology 2. (143 - 174). Butterworth-Heinemann: Oxford.

Turner, C; Jones, L; Cooper, JM; Schapira, AHV; (2002) The characterization of Huntington's disease (HD) skeletal muscle: Mitochondrial respiratory chain, ultrastructural and light microscopic study. In: MOVEMENT DISORDERS. (pp. S325 - S325). WILEY-LISS

Turner, C; Jones, L; Elliston, L; Cooper, JM; Schapira, AHV; (2002) In vitro cell models of Huntington's disease using N-terminal and full-length huntingtin: The relationship between excitotoxicity, mitochondrial dysfunction, and free radicals. In: MOVEMENT DISORDERS. (pp. S320 - S321). WILEY-LISS

Turner, C; Schapira, AH; (2002) Energy metabolism and Huntington's Disease. In: Bates, GP and Harper, P and Jones, L, (eds.) Huntington's Disease. (309 - 323). Oxford University Press: Oxford.

2001

Bhatia, K; Brooks, DJ; Burn, DJ; Clarke, CE; Grosset, DG; MacMahon, DG; ... Parkinsons Dis Consensus Working G,; + view all (2001) Updated guidelines for the management of Parkinson's disease. HOSP MED , 62 (8) 456 - 470.

Cleeter, MW; Cooper, JM; Schapira, AH; (2001) Nitric Oxide enhances MPP+ inhibition of complex I. FEBS Letters , 24 (502(1-2)) 50 - 52. 10.1016/S0014-5793(01)02763-6.

Cleeter, MWJ; Cooper, JM; Schapira, AHV; (2001) Nitric oxide enhances MPP+ inhibition of complex I. FEBS LETT , 504 (1-2) 50 - 52.

Cock, HR; Schapira, AHV; (2001) Mitochondrial myopathies. In: Rose, FC, (ed.) Twentieth Century Neurology: The British Contribution. (255 - 281). Imperial College Press: London.

King, DF; Cooper, JM; Schapira, AHV; (2001) Pramipexole protects against MPP+ toxicity in SHSY5Y cells by maintaining mitochondrial membrane potential. NEUROLOGY , 56 (8) A377 - A378.

Kingsbury, AE; Cooper, M; Schapira, AHV; Foster, OJF; (2001) Metabolic enzyme expression in dopaminergic neurons in Parkinson's disease: An in situ hybridization study. ANN NEUROL , 50 (2) 142 - 149.

Lodi, R; Hart, PE; Rajagopalan, B; Taylor, DJ; Crilley, JG; Bradley, JL; ... Cooper, JM; + view all (2001) Antioxidant treatment improves in vivo cardiac and skeletal muscle bioenergetics in patients with Friedreich's ataxia. ANN NEUROL , 49 (5) 590 - 596.

Lodi, R; Rajagopalan, B; Blamire, AM; Cooper, JM; Davies, CH; Bradley, JL; ... Schapira, AHV; + view all (2001) Cardiac energetics are abnormal in Friedreich ataxia patients in the absence of cardiac dysfunction and hypertrophy: An in vivo P-31 magnetic resonance spectroscopy study. CARDIOVASC RES , 52 (1) 111 - 119.

Lodi, R; Taylor, DJ; Schapira, AHV; (2001) Mitochondrial dysfunction in Friedreich's ataxia. BIOL SIGNAL RECEPT , 10 (3-4) 263 - 270.

Lodi, R.; Hart, P.E.; Rajagopalan, B.; Taylor, D.J.; Crilley, J.G.; Bradley, J.L.; ... Cooper, J.M.; + view all (2001) Antioxidant treatment improves in vivo cardiac and skeletal muscle bioenergetics in patients with Friedreich's ataxia. Annals of Neurology , 49 (5) pp. 590-596. 10.1002/ana.1001.

Lodi, R.; Rajagopalan, B.; Blamire, A.M.; Cooper, J.M.; Davies, C.H.; Bradley, J.L.; ... Schapira, A.H.V.; + view all (2001) Cardiac energetics are abnormal in Friedreich ataxia patients in the absence of cardiac dysfunction and hypertrophy: an in vivo 31P magnetic resonance spectroscopy study. Cardiovascular Research , 52 (1) pp. 111-119. 10.1016/S0008-6363(01)00357-1.

Orrell, R; Schapira, AHV; (2001) Asymmetric muscle weakness. In: Schapira, AHV and Rowland, LP, (eds.) Clinical cases in neurology. (239 - 245). Butterworth-Heinemann: Oxford.

Orrell, R; Schapira, AHV; (2001) Muscle weakness and dysphagia. In: Schapira, AHV and Rowland, LP, (eds.) Clinical cases in neurology. (99 - 106). Butterworth-Heinemann: Oxford.

Orth, M; Schapira, AHV; (2001) Prion codon 129 homozygosity and sporadic inclusion body myositis - Reply. NEUROLOGY , 57 (2) 368 - 368.

Orth, M; Schapira, AHV; (2001) Mitochondria and degenerative disorders. AM J MED GENET , 106 (1) 27 - 36.

Page, RA; Davie, CA; MacManus, D; Dooley, J; Walshe, J; Miller, DH; ... Schapira, AHV; + view all (2001) Magnetic resonance spectroscopy of patients with Wilson's disease. J NEUROL NEUROSUR PS , 70 (2) 274 - 275.

Rafique, R; Schapira, AHV; Cooper, JM; (2001) Sensitivity of respiratory chain activities to lipid peroxidation: effect of vitamin E deficiency. BIOCHEM J , 357 887 - 892.

Rafique, R.; Schapira, A.H.V.; Cooper, J.M.; (2001) Sensitivity of respiratory chain activities to lipid peroxidation: effect of vitamin E deficiency. Biochemical Journal , 357 (3) pp. 887-892. 10.1042/0264-6021:3570887.

Schapira, A; Ed,; (2001) Clinical cases in neurology. Butterworth-Heinemann: Oxford.

Schapira, AHV; (2001) Causes of neuronal death in Parkinson's disease. ADV NEUROL , 86 155 - 162.

Schapira, AHV; Orrell, R; (2001) Young onset stroke. In: Schapira, AHV and Rowland, LP, (eds.) Clinical cases in neurology. (177 - 182). Butterworth-Heinemann: Oxford.

Sharma, P; Wang, T; Brown, MJ; Schapira, AHV; (2001) Fits and strokes. LANCET , 358 (9276) 120 - 120.

Shults, CW; Schapira, AHV; (2001) A cue to queue for CoQ? NEUROLOGY , 57 (3) 375 - 376.

Silva, MT; Schapira, AHV; (2001) Parkinson's disease. In: Mattson, MP, (ed.) Pathogenesis of neurodegenerative disorders. (53 - 79). Humana Press: Totowa,N.J..

Turner, C; Schapira, AHV; (2001) Mitochondrial dysfunction in neurodegenerative disorders and ageing. NEUROPATHOLOGY AND GENETICS OF DEMENTIA , 487 229 - 251.

Williams, SL; Scholte, HR; Gray, RGF; Leonard, JV; Schapira, AHV; Taanman, JW; (2001) Immunological phenotyping of fibroblast cultures from patients with a mitochondrial respiratory chain deficit. LAB INVEST , 81 (8) 1069 - 1077.

Wyttenbach, A; Swartz, J; Kita, H; Thykjaer, T; Carmichael, J; Bradley, J; ... Rubinsztein, DC; + view all (2001) Polyglutamine expansions cause decreased CRE-mediated transcription and early gene expression changes prior to cell death in an inducible cell model of Huntington's disease. Hum Mol Genet , 10 (17) 1829 - 1845.

2000

Attimonelli, M; Altamura, N; Benne, R; Brennicke, A; Cooper, JM; D'Elia, D; ... Saccone, C; + view all (2000) MitBASE: a comprehensive and integrated mitochondrial DNA database. The present status. NUCLEIC ACIDS RES , 28 (1) 148 - 152. Gold open access

Bradley, JL; Blake, JC; Chamberlain, S; Thomas, PK; Cooper, JM; Schapira, AHV; (2000) Clinical, biochemical and molecular genetic correlations in Friedreich's ataxia. HUM MOL GENET , 9 (2) 275 - 282.

Gu, M; Cooper, JM; Butler, P; Walker, AP; Mistry, PK; Dooley, JS; Schapira, AHV; (2000) Oxidative phosphorylation defects in Wilson's disease liver. HEPATOLOGY , 32 (4) 487A - 487A.

Gu, M; Cooper, JM; Butler, P; Walker, AP; Mistry, PK; Dooley, JS; Schapira, AHV; (2000) Oxidative-phosphorylation defects in liver of patients with Wilson's disease. LANCET , 356 (9228) 469 - 474.

Leonard, JV; Schapira, AHV; (2000) Mitochondrial respiratory chain disorders II: neurodegenerative disorders and nuclear gene defects. LANCET , 355 (9201) 389 - 394.

Leonard, JV; Schapira, AHV; (2000) Mitochondrial respiratory chain disorders I: mitochondrial DNA defects. LANCET , 355 (9200) 299 - 304.

Lo, SK; Tolner, B; Rogers, G; Schapira, AHV; Hartley, JA; Hochhauser, D; (2000) Assessment of mitochondrial DNA damage by chemotherapeutic agents. BRIT J CANCER , 83 22 - 22.

Lodi, R; Schapira, AHV; Manners, D; Styles, P; Wood, NW; Taylor, DJ; Warner, TT; (2000) Abnormal in vivo skeletal muscle energy metabolism in Huntington's disease and dentatorubropallidoluysian atrophy. ANN NEUROL , 48 (1) 72 - 76.

Munchau, A; Valente, EM; Shahidi, GA; Eunson, LH; Hanna, RG; Quinn, NP; ... Bhatia, KP; + view all (2000) A new family with paroxysmal exercise induced dystonia and migraine: a clinical and genetic study. J NEUROL NEUROSUR PS , 68 (5) 609 - 614.

Olanow, CW; Schapira, AHV; Rascol, O; (2000) Continuous dopamine-receptor stimulation in early Parkinson's disease. TRENDS NEUROSCI , 23 (10) S117 - S126.

Olanow, CW; Schapira, AHV; Rascol, O; (2000) Continous dopamine-receptor stimulation in early Parkinson's disease. Trends in Neurosciences , 23(iss (10 Sup) S117 - S126.

Olanow, CW; Schapira, AHV; Roth, T; (2000) Waking up to sleep episodes in Parkinson's disease. MOVEMENT DISORD , 15 (2) 212 - 215.

Olanow, CW; Schapira, AHV; Roth, T; (2000) Falling asleep at the wheel: Motor vehicle mishaps in people taking pramipexole and ropinirole. NEUROLOGY , 54 (1) 274 - 274.

Orth, M; Tabrizi, SJ; Schapira, AHV; (2000) Sporadic inclusion body myositis not linked to prion protein codon 129 methionine homozygosity. NEUROLOGY , 55 (8) 1235 - 1235.

Rahman, S; Lake, BD; Taanman, JW; Hanna, MG; Cooper, JM; Schapira, AHV; Leonard, JV; (2000) Cytochrome oxidase immunohistochemistry: clues for genetic mechanisms. BRAIN , 123 591 - 600.

Schapira, AHV; (2000) Overview: sleep disturbances in Parkinson's disease. EUR J NEUROL , 7 1 - 2.

Schapira, AHV; (2000) The aetiology and management of sleep episodes in Parkinson's disease. EUROPEAN JOURNAL OF NEUROLOGY , 7 36 - 40.

Schapira, AHV; (2000) Mitochondrial disorders. CURR OPIN NEUROL , 13 (5) 527 - 532.

Schapira, AHV; (2000) Sleep attacks (sleep episodes) with pergolide. LANCET , 355 (9212) 1332 - 1333.

Schapira, AHV; (2000) Parkinson's disease: examining neuroprotective strategies. Geriatric Medicine , 30 (11) 39 - 42.

Schapira, AHV; Obeso, JA; Olanow, CW; (2000) The place of COMT inhibitors in the armamentarium of drugs for the treatment of Parkinson's disease. NEUROLOGY , 55 (11) S65 - S68.

Taanman, JW; Williams, SL; Morris, AAM; Cooper, JM; Clayton, PT; Leonard, JV; Schapira, AHV; (2000) Mitochondrial DNA depletion syndrome: A familial disorder showing variable clinical penetration. ANN NEUROL , 48 (3) 438 - 438.

Tabrizi, SJ; Orth, M; Wilkinson, JM; Taanman, JW; Warner, TT; Cooper, JM; Schapira, AHV; (2000) Expression of mutant alpha-synuclein causes increased susceptibility to dopamine toxicity. HUM MOL GENET , 9 (18) 2683 - 2689.

Tabrizi, SJ; Workman, J; Hart, PE; Mangiarini, L; Mahal, A; Bates, G; ... Schapira, AHV; + view all (2000) Mitochondrial dysfunction and free radical damage in the Huntington R6/2 transgenic mouse. ANN NEUROL , 47 (1) 80 - 86.

1999

Attimonelli, M; Altamura, N; Benne, R; Boyen, C; Brennicke, A; Carone, A; ... Saccone, C; + view all (1999) MitBASE: a comprehensive and integrated mitochondrial DNA database. NUCLEIC ACIDS RES , 27 (1) 128 - 133. Gold open access

Attimonelli, M; Cooper, JM; D'Elia, D; de Montalvo, A; De Robertis, M; Lehvaslaiho, H; ... Saccone, C; + view all (1999) Update of the human MitBASE database. NUCLEIC ACIDS RES , 27 (1) 143 - 146. Gold open access

Blake, JC; Taanman, JW; Morris, AMM; Gray, RGF; Cooper, JM; McKiernan, PJ; ... Schapira, AHV; + view all (1999) Mitochondrial DNA depletion syndrome is expressed in amniotic fluid cell cultures. AM J PATHOL , 155 (1) 67 - 70.

Chalmers, RM; Schapira, AHV; (1999) Clinical, biochemical and molecular genetic features of Leber's hereditary optic neuropathy. BBA-BIOENERGETICS , 1410 (2) 147 - 158.

Cock, H; Schapira, AHV; (1999) Mitochondrial DNA mutations and mitochondrial dysfunction in epilepsy. EPILEPSIA , 40 33 - 40.

Cock, HR; Cooper, JM; Schapira, AHV; (1999) Functional consequences of the 3460-bp mitochondrial DNA mutation associated with Leber's hereditary optic neuropathy. J NEUROL SCI , 165 (1) 10 - 17.

Hart, PE; Schapira, AHV; (1999) Mitochondria: Aspects for neuroprotection. DRUG DEVELOP RES , 46 (1) 57 - 66.

Lodi, R; Cooper, JM; Bradley, JL; Manners, D; Styles, P; Taylor, DJ; Schapira, AHV; (1999) Deficit of in vivo mitochondrial ATP production in patients with Friedreich ataxia. P NATL ACAD SCI USA , 96 (20) 11492 - 11495.

Newman, B; Meola, G; O'Donovan, DG; Schapira, AHV; Kingston, H; (1999) Proximal myotonic myopathy (PROMM) presenting as myotonia during pregnancy. NEUROMUSCULAR DISORD , 9 (3) 144 - 149.

Obeso, J; Olanow, W; Schapira, AHV; Toloso, J; (1999) Neuronal death and Parkinson's disease. Adis: Madrid.

Rahman, S; Schapira, AHV; (1999) Mitochondrial myopathies: clinical features, molecular genetics, investigation, and management. In: Schapira, AHV and Griggs, RC, (eds.) Muscle diseases. (117 - 223). Butterworth Heinemann: Boston.

Rahman, S; Taanman, JW; Cooper, JM; Nelson, I; Hargreaves, I; Meunier, B; ... Schapira, AHV; + view all (1999) A missense mutation of cytochrome oxidase subunit II causes defective assembly and myopathy. AM J HUM GENET , 65 (4) 1030 - 1039.

Schapira, AH; (1999) Mitochondrial DNA in Parkinson's disease. In: UNSPECIFIED (233 - 237).

Schapira, AHV; (1999) Mitochondria in the aetiology and pathogenesis of Parkinson's disease. PARKINSONISM RELAT D , 5 (4) 139 - 143.

Schapira, AHV; (1999) Mitochondrial disorders. BBA-BIOENERGETICS , 1410 (2) 99 - 102.

Schapira, AHV; (1999) Mitochondrial involvement in Parkinson's disease, Huntington's disease, hereditary spastic paraplegia and Friedreich's ataxia. BBA-BIOENERGETICS , 1410 (2) 159 - 170.

Schapira, AHV; (1999) Science, medicine, and the future - Parkinson's disease. BRIT MED J , 318 (7179) 311 - 314.

Schapira, AHV; (1999) Aetiology of Parkinson's disease. In: Obeso, J and Olanow, W and Schapira, AHV and Toloso, J, (eds.) Neuronal death and Parkinson's disease. (41 - 49). Adis: Madrid.

Schapira, AHV; (1999) Looking ahead in the treatment of Parkinson's disease. Geriatric Medicine , 28 59 - 62.

Schapira, AHV; (1999) Mitochondrial dysfunction in neurodegenerative diseases. Neuroscience News , 2 (5) 43 - 49.

Schapira, AHV; (1999) Mitochondrial dysfunction in Parkinson's disease. In: Obeso, J and Olanow, W and Schapira, AHV and Toloso, J, (eds.) Neuronal death and Parkinson's disease. (109 - 120). Adis: Madrid.

Schapira, AHV; Cock, HR; (1999) Mitochondrial myopathies and encephalomyopathies. EUR J CLIN INVEST , 29 (10) 886 - 898.

Tabrizi, SJ; Cleeter, MWJ; Xuereb, J; Taanman, JW; Cooper, JM; Schapira, AHV; (1999) Biochemical abnormalities and excitotoxicity in Huntington's disease brain. ANN NEUROL , 45 (1) 25 - 32.

Tabrizi, SJ; Schapira, AHV; (1999) Secondary abnormalities of mitochondrial DNA associated with neurodegeneration. MITOCHONDRIA AND CELL DEATH (66) 99 - 110.

1998

Attimonelli, M; Calo, D; Cooper, JM; de Montalvo, A; Licciulli, F; Sasanelli, D; ... Shapira, AHV; + view all (1998) The mitBASE human dataset structure. NUCLEIC ACIDS RESEARCH , 26 (1) 116 - 119. 10.1093/nar/26.1.116. Gold open access

Bhatia, K; Brooks, DJ; Burn, DJ; Clarke, CE; Playfer, J; Sawle, GV; ... Williams, AC; + view all (1998) Guidelines for the management of Parkinson's disease. The Parkinson's Disease Consensus Working Group. Hosp Med , 59 (6) 469 - 480.

Bhatia, K; Brooks, DJ; Burn, DJ; Clarke, CE; Playfer, J; Sawle, GV; ... Parkinson Dis Consensus Working Grp,; + view all (1998) Guidelines for the management of Parkinson's disease. HOSP MED , 59 (6) 469 - 480.

Cock, H; Taanman, J-W; Schapira, AHV; (1998) Mitochondrial DNA mutations and nuclear mitochondrial interactions in human disease. In: Papa, C and Guerrieri, F and Tager, JM, (eds.) Frontiers of cellular bioenergetics: molecular biology, biochemistry, and physiopathology. (635 - 663). Pleum Pub Corp: London.

Cock, HR; Tabrizi, SJ; Cooper, JM; Schapira, AHV; (1998) The influence of nuclear background on the biochemical expression of 3460 Leber's hereditary optic neuropathy. ANN NEUROL , 44 (2) 187 - 193.

Gu, M; Cooper, JM; Taanman, JW; Schapira, AHV; (1998) Mitochondrial DNA transmission of the mitochondrial defect in Parkinson's disease. ANN NEUROL , 44 (2) 177 - 186.

Gu, M; Owen, AD; Toffa, SEK; Cooper, JM; Dexter, DT; Jenner, P; ... Schapira, AHV; + view all (1998) Mitochondrial function, GSH and iron in neurodegeneration and Lewy body diseases. J NEUROL SCI , 158 (1) 24 - 29.

Hanna, MG; Nelson, IP; Rahman, S; Lane, RJM; Land, J; Heales, S; ... Wood, NW; + view all (1998) Cytochrome c oxidase deficiency associated with the first stop-codon point mutation in human mtDNA. AM J HUM GENET , 63 (1) 29 - 36.

Hanna, MG; Stewart, J; Schapira, AHV; Wood, NW; Morgan-Hughes, JA; Murray, NMF; (1998) Salbutamol treatment in a patient with hyperkalaemic periodic paralysis due to a mutation in the skeletal muscle sodium channel gene (SCN4A). J NEUROL NEUROSUR PS , 65 (2) 248 - 250.

Lees, AJ; Lang, AE; (1998) Movement disorders. (Vol.13).

Lodi, R; Cooper, JM; Manners, D; Styles, P; Taylor, DJ; Schapira, AHV; (1998) Deficit of mitochondrial respiration in patients with Friedreich's ataxia shown by in vivo P-31 magnetic resonance spectroscopy. ANN NEUROL , 44 (3) 439 - 440.

Lodi, R; Taylor, DJ; Tabrizi, SJ; Hilton-Jones, D; Squier, MV; Seller, A; ... Schapira, AHV; + view all (1998) Normal in vivo skeletal muscle oxidative metabolism in sporadic inclusion body myositis assessed by P-31-magnetic resonance spectroscopy. BRAIN , 121 2119 - 2126.

Morris, AAM; Taanman, JW; Blake, J; Cooper, JM; Lake, BD; Malone, M; ... Schapira, AHV; + view all (1998) Liver failure associated with mitochondrial DNA depletion. J HEPATOL , 28 (4) 556 - 563.

Schapira, AH; (1998) Colloidal gold staining and immunodetection in 2D protein mapping. In: UNSPECIFIED (237 - 241).

Schapira, AHV; (1998) Inborn and induced defects of mitochondria. ARCH NEUROL-CHICAGO , 55 (10) 1293 - 1296.

Schapira, AHV; (1998) Mitochondrial dysfunction in neurodegenerative disorders. BBA-BIOENERGETICS , 1366 (1-2) 225 - 233.

Schapira, AHV; (1998) Human complex I defects in neurodegenerative diseases. BBA-BIOENERGETICS , 1364 (2) 261 - 270.

Schapira, AHV; (1998) Diseases of muscle and the neuromuscular junction. In: Marsden, CD and Fowler, TJ, (eds.) Clinical Neurology. (105 - 125). Arnold: London.

Schapira, AHV; Gu, M; Taanman, JW; Tabrizi, SJ; Seaton, T; Cleeter, M; Cooper, JM; (1998) Mitochondria in the etiology and pathogenesis of Parkinson's disease. ANNALS OF NEUROLOGY , 44 (3) S89 - S98.

Seaton, TA; Cooper, JM; Schapira, AHV; (1998) Cyclosporin inhibition of apoptosis induced by mitochondrial complex I toxins. BRAIN RES , 809 (1) 12 - 17.

Tabrizi, SJ; Cooper, JM; Schapira, AHV; (1998) Mitochondrial DNA in focal dystonia: A cybrid analysis. ANN NEUROL , 44 (2) 258 - 261.

Tabrizi, SJ; Schapira, AHV; (1998) Primary and secondary deficiencies of the mitochondrial respiratory chain. NEUROLOGIST , 4 (4) 169 - 179.

Turner, LF; Kaddoura, S; Harrington, D; Cooper, JM; Poole-Wilson, PA; Schapira, AHV; (1998) Mitochondrial DNA in idiopathic cardiomyopathy. EUR HEART J , 19 (11) 1725 - 1729.

Warner, TT; Schapira, AHV; (1998) The role of the alpha-synuclein gene mutation in patients with sporadic Parkinson's disease in the United Kingdom. J NEUROL NEUROSUR PS , 65 (3) 378 - 379.

1997

Blake, JC; Taanman, JW; Leonard, JV; Cooper, JM; Schapira, AHV; (1997) Molecular mechanisms in mitochondrial DNA depletion syndrome. NEUROLOGY , 48 (3) 4082 - 4082.

Cock, H; Mandler, R; Ahmed, W; Schapira, AHV; (1997) Neuromyelitis optica (Devic's syndrome): No association with the primary mitochondrial DNA mutations found in Leber hereditary optic neuropathy. J NEUROL NEUROSUR PS , 62 (1) 85 - 87.

Cooper, JM; Schapira, AHV; (1997) Mitochondrial dysfunction in neurodegeneration. J BIOENERG BIOMEMBR , 29 (2) 175 - 183.

Gu, M; Gash, MT; Cooper, JM; Wenning, GK; Daniel, SE; Quinn, NP; ... Schapira, AHV; + view all (1997) Mitochondrial respiratory chain function in multiple system atrophy. MOVEMENT DISORD , 12 (3) 418 - 422.

Hanna, MG; Nelson, IP; Rahman, S; Schapira, AHV; MorganHughes, JA; Wood, NW; (1997) Cytochrome c oxidase deficiency associated with a new stop codon mutation in mitochondrial DNA. In: ANN NEUROL. (pp. M79 - M79). LIPPINCOTT-RAVEN PUBL

Hawkes, CH; Macdonald, AM; Schapira, AHV; (1997) Use of general practitioner computerised records to create a population based twin sample: pilot study based on Parkinson's disease. BRIT MED J , 315 (7121) 1510 - 1511.

Lodi, R; Taylor, DJ; Tabrizi, SJ; Kumar, S; Sweeney, M; Wood, NW; ... Schapira, AHV; + view all (1997) In vivo skeletal muscle mitochondrial function in Leber's hereditary optic neuropathy assessed by P-31 magnetic resonance spectroscopy. ANN NEUROL , 42 (4) 573 - 579.

Nashef, L; Lake, BD; Schapira, AHV; (1997) Congenital muscular dystrophy with severe retrocollis and mental retardation: A report of two siblings. J NEUROL NEUROSUR PS , 62 (3) 279 - 281.

Olanow, CW; Schapira, AHV; (1997) Neuroprotection in Parkinson's disease. In: Bar, PR and Beal, MF, (eds.) Neuroprotection in CNS diseases. (425 - 445). Marcel Dekker: New York.

Owen, AD; Schapira, AHV; Jenner, P; Marsden, CD; (1997) Indices of oxidative stress in Parkinson's disease, Alzheimer's disease and dementia with Lewy bodies. J NEURAL TRANSM-SUPP (51) 167 - 173.

Rees, JH; Ginsberg, L; Schapira, AHV; (1997) Two pregnant women with vomiting and fits. AM J OBSTET GYNECOL , 177 (6) 1539 - 1540.

Schapira, A; (1997) Mitochondrial Mutations in Human Disease.

Schapira, AHV; (1997) Mitochondrial disorders: An overview. J BIOENERG BIOMEMBR , 29 (2) 105 - 107.

Schapira, AHV; (1997) Pathogenesis of Parkinson's disease. In: UNSPECIFIED (15 - 36). BAILLIERE TINDALL

Schapira, AHV; (1997) Mitochondrial disorders. CURR OPIN NEUROL , 10 (1) 43 - 47.

Schapira, AHV; (1997) Mitochondrial function in Huntington's disease: Clues for pathogenesis and prospects for treatment. ANN NEUROL , 41 (2) 141 - 142.

Schapira, AHV; (1997) Future studies. In: Olanow, CW and Obeso, JA, (eds.) Beyond the decade of the brain. (233 - 238). Wells Medical: Kent.

Schapira, AHV; (1997) Mitochondrial dysfunction and oxidative damage in Parkinson's disease. In: Beal, MF and Howell, N and Bodis-Wollner, I, (eds.) Mitochondrial and free radicals in neurodegenerative diseases. (343 - 358). John Wiley: New York.

Schapira, AHV; Warner, T; Gash, MT; Cleeter, MWJ; Marinho, CFM; Copper, JM; (1997) Complex I function in familial and sporadic dystonia. ANN NEUROL , 41 (4) 556 - 559.

Seaton, TA; Cooper, JM; Schapira, AHV; (1997) Free radical scavengers protect dopaminergic cell lines from apoptosis induced by complex I inhibitors. BRAIN RES , 777 (1-2) 110 - 118.

Silva, MT; Schapira, AHV; Jenner, P; (1997) Unexpected findings of study of selegiline have not been treated with caution its authors advised. BRIT MED J , 315 (7104) 370 - 370.

Taanman, JW; Bodnar, AG; Cooper, JM; Morris, AAM; Clayton, PT; Leonard, JV; Schapira, AHV; (1997) Molecular mechanisms in mitochondrial DNA depletion syndrome. HUM MOL GENET , 6 (6) 935 - 942.

Tabrizi, SJ; Cooper, JM; Xuereb, JH; Schapira, AHV; (1997) Mechanisms involved in the pathogenesis of Huntington's disease. ANN NEUROL , 42 (3) T202 - T202.

Warner, TT; Schapira, AHV; (1997) Genetic counselling in mitochondrial diseases. CURR OPIN NEUROL , 10 (5) 408 - 412.

Warner, TT; Schapira, AHV; (1997) Mitochondrial dysfunction in neurodegeneration. Current Opinion in Neurology , 10 408 - 412.

1996

Chalmers, RM; Govan, GG; Schapira, AHV; Harding, AE; (1996) HLA class I genotypes in Leber's hereditary optic neuropathy. J NEUROL SCI , 135 (2) 173 - 175.

Cooper, JM; Schapira, AH; (1996) Biochemical investigation of mitochondrial respiratory chain abnormalities. In: Lane, R, (ed.) Hand Bood of Muscle Disease. (519 - ?). Marcel Dekker

Gu, M; Gash, MT; Mann, VM; JavoyAgid, F; Cooper, JM; Schapira, AHV; (1996) Mitochondrial defect in Huntington's disease on caudate nucleus. ANN NEUROL , 39 (3) 385 - 389.

Owen, AD; Schapira, AHV; Jenner, P; Marsden, CD; (1996) Oxidative stress and Parkinson's disease. PHARMACOLOGICAL INTERVENTION IN AGING AND AGE-ASSOCIATED DISORDERS , 786 217 - 223.

Schapira, AHV; (1996) Oxidative stress and mitochondrial dysfunction in neurodegeneration. CURR OPIN NEUROL , 9 (4) 260 - 264.

Schapira, AHV; (1996) Neurotoxicity and the mechanisms of cell death in Parkinson's disease. PARKINSON'S DISEASE , 69 161 - 165.

Shergill, JK; Cammack, R; Cooper, CE; Cooper, JM; Mann, VM; Schapira, AHV; (1996) Detection of nitrosyl complexes in human substantia nigra, in relation to Parkinson's disease. BIOCHEM BIOPH RES CO , 228 (2) 298 - 305.

Turner, LF; Kaddoura, S; Cooper, JM; Schapira, AHV; PooleWilson, PA; (1996) Previously-reported mitochondrial DNA mutations are not a common cause of idiopathic dilated cardiomyopathy. HEART , 75 (5) 201 - 201.

1995

BODNAR, AG; COOPER, JM; LEONARD, JV; SCHAPIRA, AHV; (1995) RESPIRATORY-DEFICIENT HUMAN FIBROBLASTS EXHIBITING DEFECTIVE MITOCHONDRIAL-DNA REPLICATION. BIOCHEM J , 305 817 - 822.

COCK, HR; COOPER, JM; SCHAPIRA, AHV; (1995) THE 14484-ND6 MTDNA MUTATION IN LEBER HEREDITARY OPTIC NEUROPATHY DOES NOT AFFECT FIBROBLAST COMPLEX-I ACTIVITY. AM J HUM GENET , 57 (6) 1501 - 1502.

COCK, HR; COOPER, JM; SCHAPIRA, AHV; (1995) NUCLEAR COMPLEMENTATION IN LEBER HEREDITARY OPTIC NEUROPATHY. NEUROLOGY , 45 (4) A294 - A294.

COOPER, JM; DANIEL, SE; MARSDEN, CD; SCHAPIRA, AHV; (1995) L-DIHYDROXYPHENYLALANINE AND COMPLEX-I DEFICIENCY IN PARKINSONS-DISEASE BRAIN. MOVEMENT DISORD , 10 (3) 295 - 297.

MORGANHUGHES, JA; SWEENEY, MG; COOPER, JM; HAMMANS, SR; BROCKINGTON, M; SCHAPIRA, AHV; ... CLARK, JB; + view all (1995) MITOCHONDRIAL-DNA (MTDNA) DISEASES - CORRELATION OF GENOTYPE TO PHENOTYPE. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE , 1271 (1) 135 - 140.

Schapira, AH; (1995) Nuclear and mitochondrial genetics in Parkinson's disease. J Med Genet , 32 (6) 411 - 414.

SCHAPIRA, AHV; (1995) HARDING,ANITA - OBITUARY. BRIT MED J , 311 (7012) 1085 - 1085.

SCHAPIRA, AHV; (1995) OXIDATIVE STRESS IN PARKINSONS-DISEASE. NEUROPATH APPL NEURO , 21 (1) 3 - 9.

SCHAPIRA, AHV; (1995) Mitochondria, free radicals, neurodegeneration and aging. In: Cutler, RG and Packer, L and Bertram, J and Mori, A, (eds.) OXIDATIVE STRESS AND AGING. (pp. 159 - 169). BIRKHAUSER VERLAG

Schapira, AHV; (1995) The role of mitochondrial dysfunction in neurodegenerative disease. In: Esser, K and Martin, GM, (eds.) MOLECULAR ASPECTS OF AGING. (pp. 241 - 251). JOHN WILEY & SONS LTD

SCHAPIRA, AHV; REICHMANN, H; (1995) ELECTRON-TRANSPORT CHAIN DEFECTS IN ALZHEIMERS-DISEASE. NEUROLOGY , 45 (3) 599 - 600.

SMITH, PR; COOPER, JM; GOVAN, GG; RIORDANEVA, P; HARDING, AE; SCHAPIRA, AHV; (1995) ANTIBODIES TO HUMAN OPTIC-NERVE IN LEBERS HEREDITARY OPTIC NEUROPATHY. J NEUROL SCI , 130 (2) 134 - 138.

1994

CLEETER, MWJ; COOPER, JM; DARLEYUSMAR, VM; MONCADA, S; SCHAPIRA, AHV; (1994) REVERSIBLE INHIBITION OF CYTOCHROME-C-OXIDASE, THE TERMINAL ENZYME OF THE MITOCHONDRIAL RESPIRATORY-CHAIN, BY NITRIC-OXIDE - IMPLICATIONS FOR NEURODEGENERATIVE DISEASES. FEBS LETT , 345 (1) 50 - 54.

Cooper, JM; Clark, JB; (1994) Abnormalities of mitochondrial respiratory chain complexes I-III in humans. In: Darley-Usmar, V and Schapira, AH, (eds.) UNSPECIFIED Portland Press

Cooper, JM; Clarke, JB; (1994) The structural organisaton of the mitochondrial respiratory chain. In: Mitochondrial Disorders in Neurology. (1 - 30). Butterworth-Heinemann

DEXTER, DT; SIAN, J; ROSE, S; HINDMARSH, JG; MANN, VM; COOPER, JM; ... MARSEN, CD; + view all (1994) INDEXES OF OXIDATIVE STRESS AND MITOCHONDRIAL-FUNCTION IN INDIVIDUALS WITH INCIDENTAL LEWY BODY DISEASE. ANN NEUROL , 35 (1) 38 - 44.

GOVAN, GG; SMITH, PR; KELLARWOOD, H; SCHAPIRA, AHV; HARDING, AE; (1994) HLA CLASS-II GENOTYPES IN LEBERS HEREDITARY OPTIC NEUROPATHY. J NEUROL SCI , 126 (2) 193 - 196.

HARTLEY, A; STONE, JM; HERON, C; COOPER, JM; SCHAPIRA, AHV; (1994) COMPLEX-I INHIBITORS INDUCE DOSE-DEPENDENT APOPTOSIS IN PC12 CELLS - RELEVANCE TO PARKINSONS-DISEASE. J NEUROCHEM , 63 (5) 1987 - 1990.

MANN, VM; COOPER, JM; DANIEL, SE; SRAI, K; JENNER, P; MARSDEN, CD; SCHAPIRA, AHV; (1994) COMPLEX-I, IRON, AND FERRITIN IN PARKINSONS-DISEASE SUBSTANTIA-NIGRA. ANN NEUROL , 36 (6) 876 - 881.

Schapira, AH; Cooper, JM; (1994) Biochemical and molecular features of deficiencies of complex I,II and III. In: Schapira, AHD and S,, (eds.) UNSPECIFIED (75 - 90). Butterworth-Heinemann

SCHAPIRA, AHV; (1994) MITOCHONDRIAL-FUNCTION AND NEUROTOXICITY. CURR OPIN NEUROL , 7 (6) 531 - 534.

SCHAPIRA, AHV; (1994) SCHAPIRA,MARKUS - OBITUARY. BRIT MED J , 309 (6962) 1155 - 1155.

SCHAPIRA, AHV; (1994) ADVANCES IN THE UNDERSTANDING OF THE CAUSE OF PARKINSONS-DISEASE. J ROY SOC MED , 87 (7) 373 - 375.

SCHAPIRA, AHV; (1994) EVIDENCE FOR MITOCHONDRIAL DYSFUNCTION IN PARKINSONS-DISEASE - A CRITICAL-APPRAISAL. MOVEMENT DISORD , 9 (2) 125 - 138.

SCHAPIRA, AHV; COOPER, JM; (1994) INBORN AND INDUCED DEFECTS OF THE MITOCHONDRIAL RESPIRATORY-CHAIN. BIOCHEMICAL SOCIETY TRANSACTIONS , 22 (4) 996 - 1001.

SCHAPIRA, AHV; MARSDEN, CD; (1994) BRITISH NEUROLOGY - A NATIONAL FOCUS. J NEUROL NEUROSUR PS , 57 (9) 1136 - 1136.

SCHAPIRA, AHV; MARSDEN, CD; (1994) PLATELET MITOCHONDRIAL-DNA IN PARKINSONS-DISEASE. MOVEMENT DISORD , 9 (1) 119 - 120.

SMITH, PR; COOPER, JM; GOVAN, GG; HARDING, AE; SCHAPIRA, AHV; (1994) PLATELET MITOCHONDRIAL-FUNCTION IN LEBERS HEREDITARY OPTIC NEUROPATHY. J NEUROL SCI , 122 (1) 80 - 83.

SWEENEY, MG; HAMMANS, SR; DUCHEN, LW; COOPER, JM; SCHAPIRA, AHV; KENNEDY, CR; ... HARDING, AE; + view all (1994) MITOCHONDRIAL-DNA MUTATION UNDERLYING LEIGHS SYNDROME - CLINICAL, PATHOLOGICAL, BIOCHEMICAL, AND GENETIC-STUDIES OF A PATIENT PRESENTING WITH PROGRESSIVE MYOCLONIC EPILEPSY. J NEUROL SCI , 121 (1) 57 - 65.

TAYLOR, DJ; KRIGE, D; BARNES, PRJ; KEMP, GJ; CARROLL, MT; MANN, VM; ... SCHAPIRA, AHV; + view all (1994) A P-31 MAGNETIC-RESONANCE SPECTROSCOPY STUDY OF MITOCHONDRIAL-FUNCTION IN SKELETAL-MUSCLE OF PATIENTS WITH PARKINSONS-DISEASE. J NEUROL SCI , 125 (1) 77 - 81.

1993

BODNAR, AG; COOPER, JM; HOLT, IJ; LEONARD, JV; SCHAPIRA, AHV; (1993) NUCLEAR COMPLEMENTATION RESTORES MTDNA LEVELS IN CULTURED-CELLS FROM A PATIENT WITH MTDNA DEPLETION. AM J HUM GENET , 53 (3) 663 - 669.

BODNAR, AG; COOPER, JM; HOLT, IJ; LEONARD, JV; SCHAPIRA, AHV; (1993) NUCLEAR COMPLEMENTATION OF MITOCHONDRIAL-DNA DEPLETION SYNDROME. ANN NEUROL , 34 (2) 305 - 305.

BODNAR, AG; COOPER, JM; MORGANHUGHES, JA; SCHAPIRA, AHV; (1993) MITOCHONDRIAL MYOPATHY WITH A DEFECT IN MITOCHONDRIAL PROTEIN IMPORT. NEUROLOGY , 43 (4) A372 - A372.

COOPER, JM; WISCHIK, C; SCHAPIRA, AHV; (1993) MITOCHONDRIAL-FUNCTION IN ALZHEIMERS-DISEASE. LANCET , 341 (8850) 969 - 970.

HARTLEY, A; COOPER, JM; SCHAPIRA, AHV; (1993) IRON-INDUCED OXIDATIVE STRESS AND MITOCHONDRIAL DYSFUNCTION - RELEVANCE TO PARKINSON DISEASE. BRAIN RES , 627 (2) 349 - 353.

Schapira, AH; (1993) Mitochondrial cytopathies. Curr Opin Neurobiol , 3 (5) 760 - 767.

Schapira, AH; (1993) Mitochondrial disorders. Curr Opin Genet Dev , 3 (3) 457 - 465.

SCHAPIRA, AHV; (1993) THE USE OF TOXINS TO ELUCIDATE NEURAL FUNCTION AND DISEASE. CURR OPIN NEUROL NEU , 6 (3) 448 - 451.

SCHAPIRA, AHV; (1993) MITOCHONDRIAL COMPLEX-I DEFICIENCY IN PARKINSONS-DISEASE. In: Narabayashi, H and Nagatsu, T and Yanagisawa, N and Mizuno, Y, (eds.) PARKINSONS DISEASE : FROM BASIC RESEARCH TO TREATMENT. (pp. 288 - 291). RAVEN PRESS

SCHAPIRA, AHV; HARTLEY, A; CLEETER, MWJ; COOPER, JM; (1993) FREE-RADICALS AND MITOCHONDRIAL DYSFUNCTION IN PARKINSONS-DISEASE. BIOCHEMICAL SOCIETY TRANSACTIONS , 21 (2) 367 - 370.

SMALL, JR; THOMAS, PK; SCHAPIRA, AHV; (1993) DORSAL-ROOT GANGLION PROTEINS IN FRIEDREICHS ATAXIA. NEUROSCI LETT , 163 (2) 182 - 184.

SMITH, PR; COOPER, JM; GOVAN, GG; HARDING, AE; SCHAPIRA, AHV; (1993) SMOKING AND MITOCHONDRIAL-FUNCTION - A MODEL FOR ENVIRONMENTAL TOXINS. Q J MED , 86 (10) 657 - 660.

STEIGER, MJ; TARNESBY, G; GABE, S; MCLAUGHLIN, J; SCHAPIRA, AHV; (1993) SUCCESSFUL OUTCOME OF PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY WITH CYTARABINE AND INTERFERON. ANN NEUROL , 33 (4) 407 - 411.

THOMAS, PK; COOPER, JM; KING, RHM; WORKMAN, JM; SCHAPIRA, AHV; GOSSSAMPSON, MA; MULLER, DPR; (1993) MYOPATHY IN VITAMIN-E-DEFICIENT RATS - MUSCLE-FIBER NECROSIS ASSOCIATED WITH DISTURBANCES OF MITOCHONDRIAL-FUNCTION. J ANAT , 183 451 - 461.

1992

CLEETER, MWJ; COOPER, JM; SCHAPIRA, AHV; (1992) IRREVERSIBLE INHIBITION OF MITOCHONDRIAL COMPLEX-I BY 1-METHYL-4-PHENYLPYRIDINIUM - EVIDENCE FOR FREE-RADICAL INVOLVEMENT. J NEUROCHEM , 58 (2) 786 - 789.

COOPER, JM; MANN, VM; KRIGE, D; SCHAPIRA, AHV; (1992) HUMAN MITOCHONDRIAL COMPLEX-I DYSFUNCTION. BIOCHIMICA ET BIOPHYSICA ACTA , 1101 (2) 198 - 203.

COOPER, JM; MANN, VM; SCHAPIRA, AHV; (1992) ANALYSES OF MITOCHONDRIAL RESPIRATORY-CHAIN FUNCTION AND MITOCHONDRIAL-DNA DELETION IN HUMAN SKELETAL-MUSCLE - EFFECT OF AGING. J NEUROL SCI , 113 (1) 91 - 98.

Dexter, DT; Jenner, P; Schapira, AH; Marsden, CD; (1992) Alterations in levels of iron, ferritin, and other trace metals in neurodegenerative diseases affecting the basal ganglia. The Royal Kings and Queens Parkinson's Disease Research Group. Ann Neurol , 32 Suppl S94 - 100.

DEXTER, DT; JENNER, P; SCHAPIRA, AHV; MARSDEN, CD; (1992) ALTERATIONS IN LEVELS OF IRON, FERRITIN, AND OTHER TRACE-METALS IN NEURODEGENERATIVE DISEASES AFFECTING THE BASAL GANGLIA. In: ANNALS OF NEUROLOGY. (pp. S94 - S100). LITTLE BROWN CO

HAINES, AMR; COOPER, JM; MORGANHUGHES, JA; CLARK, JB; SCHAPIRA, AHV; (1992) ONE-STEP IMMUNOAFFINITY PURIFICATION OF COMPLEX-I SUBUNITS FROM BEEF-HEART MITOCHONDRIA. PROTEIN EXPRES PURIF , 3 (3) 223 - 227.

Jenner, P; Dexter, DT; Sian, J; Schapira, AH; Marsden, CD; (1992) Oxidative stress as a cause of nigral cell death in Parkinson's disease and incidental Lewy body disease. The Royal Kings and Queens Parkinson's Disease Research Group. Ann Neurol , 32 Suppl S82 - S87.

JENNER, P; DEXTER, DT; SIAN, J; SCHAPIRA, AHV; MARSDEN, CD; (1992) OXIDATIVE STRESS AS A CAUSE OF NIGRAL CELL-DEATH IN PARKINSONS-DISEASE AND INCIDENTAL LEWY BODY DISEASE. In: ANNALS OF NEUROLOGY. (pp. S82 - S87). LITTLE BROWN CO

JENNER, P; SCHAPIRA, AHV; MARSDEN, CD; (1992) NEW INSIGHTS INTO THE CAUSE OF PARKINSONS-DISEASE. NEUROLOGY , 42 (12) 2241 - 2250.

Krige, D; Carroll, MT; Cooper, JM; Marsden, CD; Schapira, AH; (1992) Platelet mitochondrial function in Parkinson's disease. The Royal Kings and Queens Parkinson Disease Research Group. Ann Neurol , 32 (6) 782 - 788. 10.1002/ana.410320612.

KRIGE, D; CARROLL, MT; COOPER, JM; MARSDEN, CD; SCHAPIRA, AHV; (1992) PLATELET MITOCHONDRIAL-FUNCTION IN PARKINSONS-DISEASE. ANN NEUROL , 32 (6) 782 - 788.

MANN, VM; COOPER, JM; KRIGE, D; DANIEL, SE; SCHAPIRA, AHV; MARSDEN, CD; (1992) BRAIN, SKELETAL-MUSCLE AND PLATELET HOMOGENATE MITOCHONDRIAL-FUNCTION IN PARKINSONS-DISEASE. BRAIN , 115 333 - 342.

MANN, VM; COOPER, JM; SCHAPIRA, AHV; (1992) QUANTITATION OF A MITOCHONDRIAL-DNA DELETION IN PARKINSONS-DISEASE. FEBS LETT , 299 (3) 218 - 222.

Schapira, AH; (1992) Colloidal gold staining and immunodetection in 2-d protein mapping. Methods Mol Biol , 10 255 - 259. 10.1385/0-89603-204-3:255.

Schapira, AH; (1992) Colloidal gold staining and immunodetection in 2-d protein mapping. Methods Mol Biol , 80 255 - 259. 10.1385/0-89603-204-3:255.

Schapira, AH; Mann, VM; Cooper, JM; Krige, D; Jenner, PJ; Marsden, CD; (1992) Mitochondrial function in Parkinson's disease. The Royal Kings and Queens Parkinson's Disease Research Group. Ann Neurol , 32 Suppl S116 - S124.

SCHAPIRA, AHV; (1992) MPTP AND OTHER PARKINSON-INDUCING AGENTS. CURR OPIN NEUROL NEU , 5 (3) 396 - 400.

SCHAPIRA, AHV; COOPER, JM; (1992) MITOCHONDRIAL-FUNCTION IN NEURODEGENERATION AND AGING. MUTAT RES , 275 (3-6) 133 - 143.

SCHAPIRA, AHV; MANN, VM; COOPER, JM; KRIGE, D; JENNER, PJ; MARSDEN, CD; (1992) MITOCHONDRIAL-FUNCTION IN PARKINSONS-DISEASE. In: ANNALS OF NEUROLOGY. (pp. S116 - S124). LITTLE BROWN CO

SMITH, CAD; GOUGH, AC; LEIGH, PN; SUMMERS, BA; HARDING, AE; MARANGANORE, DM; ... WOLF, CR; + view all (1992) DEBRISOQUINE HYDROXYLASE GENE POLYMORPHISM AND SUSCEPTIBILITY TO PARKINSONS-DISEASE. LANCET , 339 (8806) 1375 - 1377.

1991

GALE, AN; GIBBS, JM; SCHAPIRA, AHV; THOMAS, PK; (1991) NEUROLOGY. POSTGRAD MED J , 67 (788) 509 - 531.

MORGANHUGHES, JA; COOPER, JM; SCHAPIRA, AHV; SWEENY, M; HOLT, IJ; HARDING, AE; CLARK, JB; (1991) THE MOLECULAR PATHOLOGY OF HUMAN RESPIRATORY-CHAIN DEFECTS. REV NEUROL , 147 (6-7) 450 - 454.

SCHAPIRA, AHV; (1991) MITOCHONDRIAL NADH UBIQUINONE REDUCTASE DEFICIENCY IN PARKINSONS-DISEASE. BIOL CHEM H-S , 372 (8) 552 - 553.

1990

BET, L; BRESOLIN, N; MOGGIO, M; MEOLA, G; PRELLE, A; SCHAPIRA, AH; ... SCARLATO, G; + view all (1990) A CASE OF MITOCHONDRIAL MYOPATHY, LACTIC-ACIDOSIS AND COMPLEX-I DEFICIENCY. J NEUROL , 237 (7) 399 - 404.

COOPER, JM; SCHAPIRA, AHV; HOLT, IJ; TOSCANO, A; HARDING, AE; MORGANHUGHES, JA; CLARK, JB; (1990) BIOCHEMICAL AND MOLECULAR ASPECTS OF HUMAN MITOCHONDRIAL RESPIRATORY-CHAIN DISORDERS. BIOCHEMICAL SOCIETY TRANSACTIONS , 18 (4) 517 - 519.

HARDING, AE; HOLT, IJ; COOPER, JM; SCHAPIRA, AHV; SWEENEY, M; CLARK, JB; MORGANHUGHES, JA; (1990) MITOCHONDRIAL MYOPATHIES - GENETIC-DEFECTS. BIOCHEMICAL SOCIETY TRANSACTIONS , 18 (4) 519 - 522.

MANN, VM; COOPER, JM; JAVOYAGID, F; AGID, Y; JENNER, P; SCHAPIRA, AHV; (1990) MITOCHONDRIAL-FUNCTION AND PARENTAL SEX EFFECT IN HUNTINGTONS-DISEASE. LANCET , 336 (8717) 749 - 749.

MORGANHUGHES, JA; COOPER, JM; HOLT, IJ; HARDING, AE; SCHAPIRA, AHV; CLARK, JB; (1990) MITOCHONDRIAL MYOPATHIES - CLINICAL DEFECTS. BIOCHEMICAL SOCIETY TRANSACTIONS , 18 (4) 523 - 526.

MORGANHUGHES, JA; SCHAPIRA, AHV; COOPER, JM; HOLT, IJ; HARDING, AE; CLARK, JB; (1990) THE MOLECULAR PATHOLOGY OF RESPIRATORY-CHAIN DYSFUNCTION IN HUMAN MITOCHONDRIAL MYOPATHIES. BIOCHIM BIOPHYS ACTA , 1018 (2-3) 217 - 222.

SCHAPIRA, AHV; (1990) MITOCHONDRIAL DISORDERS. CURR OPIN NEUROL NEU , 3 (3) 425 - 430.

SCHAPIRA, AHV; COOPER, JM; DEXTER, D; CLARK, JB; JENNER, P; MARSDEN, CD; (1990) MITOCHONDRIAL COMPLEX I DEFICIENCY IN PARKINSONS-DISEASE. J NEUROCHEM , 54 (3) 823 - 827.

SCHAPIRA, AHV; COOPER, JM; MANNESCHI, L; VITAL, C; MORGANHUGHES, JA; CLARK, JB; (1990) A MITOCHONDRIAL ENCEPHALOMYOPATHY WITH SPECIFIC DEFICIENCIES OF 2 RESPIRATORY-CHAIN POLYPEPTIDES AND A CIRCULATING AUTOANTIBODY TO A MITOCHONDRIAL MATRIX PROTEIN. BRAIN , 113 419 - 432.

SCHAPIRA, AHV; COOPER, JM; MORGANHUGHES, JA; LANDON, DN; CLARK, JB; (1990) MITOCHONDRIAL MYOPATHY WITH A DEFECT OF MITOCHONDRIAL-PROTEIN TRANSPORT. NEW ENGL J MED , 323 (1) 37 - 42.

SCHAPIRA, AHV; HOLT, IJ; SWEENEY, M; HARDING, AE; JENNER, P; MARSDEN, CD; (1990) MITOCHONDRIAL-DNA ANALYSIS IN PARKINSONS-DISEASE. MOVEMENT DISORD , 5 (4) 294 - 297.

SCHAPIRA, AHV; MANN, VM; COOPER, JM; DEXTER, D; DANIEL, SE; JENNER, P; ... MARSDEN, CD; + view all (1990) ANATOMIC AND DISEASE SPECIFICITY OF NADH COQ1 REDUCTASE (COMPLEX-I) DEFICIENCY IN PARKINSONS-DISEASE. J NEUROCHEM , 55 (6) 2142 - 2145.

1989

HOLT, IJ; HARDING, AE; COOPER, JM; SCHAPIRA, AHV; TOSCANO, A; CLARK, JB; MORGANHUGHES, JA; (1989) MITOCHONDRIAL MYOPATHIES - CLINICAL AND BIOCHEMICAL FEATURES OF 30 PATIENTS WITH MAJOR DELETIONS OF MUSCLE MITOCHONDRIAL-DNA. ANN NEUROL , 26 (6) 699 - 708.

Schapira, AH; (1989) Mitochondrial myopathies. BMJ , 298 (6681) 1127 - 1128.

SCHAPIRA, AHV; (1989) MITOCHONDRIAL MYOPATHIES - MECHANISMS NOW BETTER UNDERSTOOD. BRIT MED J , 298 (6681) 1127 - 1128.

SCHAPIRA, AHV; COOPER, JM; DEXTER, D; CLARK, JB; JENNER, P; MARSDEN, CD; (1989) MITOCHONDRIAL COMPLEX-I DEFICIENCY IN PARKINSONS-DISEASE. ANN NEUROL , 26 (1) 122 - 122.

SCHAPIRA, AHV; COOPER, JM; DEXTER, D; JENNER, P; CLARK, JB; MARSDEN, CD; (1989) MITOCHONDRIAL COMPLEX I DEFICIENCY IN PARKINSONS-DISEASE. LANCET , 1 (8649) 1269 - 1269.

SCHAPIRA, AHV; LLEWELYN, JG; PATEL, NJ; THOMAS, PK; (1989) POLYPEPTIDE AND GLYCOPROTEIN ABNORMALITIES IN DORSAL-ROOT GANGLIA OF STREPTOZOTOCIN-DIABETIC RATS. J NEUROL SCI , 94 (1-3) 147 - 161.

1988

MORGANHUGHES, JA; SCHAPIRA, AHV; COOPER, JM; CLARK, JB; (1988) MOLECULAR DEFECTS OF NADH-UBIQUINONE OXIDOREDUCTASE (COMPLEX-I) IN MITOCHONDRIAL DISEASES. J BIOENERG BIOMEMBR , 20 (3) 365 - 382.

MORGANHUGHES, JA; SCHAPIRA, AHV; COOPER, JM; HAYES, DJ; CLARK, JB; (1988) HUMAN MITOCHONDRIAL RESPIRATORY-CHAIN DEFICIENCIES. AUST PAEDIATR J , 24 55 - 57.

SCHAPIRA, AHV; KEIR, G; (1988) TWO-DIMENSIONAL PROTEIN MAPPING BY GOLD STAIN AND IMMUNOBLOTTING. ANAL BIOCHEM , 169 (1) 167 - 171.

SCHAPIRA, AHV; MORGANHUGHES, JA; CLEETER, MJW; COOPER, JM; PATEL, SD; RAGAN, CI; CLARK, JB; (1988) MOLECULAR-BASIS OF MITOCHONDRIAL MYOPATHIES - POLYPEPTIDE ANALYSIS IN COMPLEX-I DEFICIENCY. LANCET , 1 (8584) 500 - 503.

1987

Morgan-Hughes, JA; Cooper, JM; Schapira, AH; Hayes, DJ; Clark, JB; (1987) The mitochondrial myopathies. Defects of the mitochondrial respiratory chain and oxidative phosphorylation system. Electroencephalogr Clin Neurophysiol Suppl , 39 103 - 114.

SCHAPIRA, AHV; COOPER, JM; MORGANHUGHES, JA; LANDON, DN; (1987) A MITOCHONDRIAL MYOPATHY WITH SPECIFIC DEFICIENCIES OF SUCCINIC-DEHYDROGENASE ACTIVITY AND THE RIESKE IRON SULFUR PROTEIN OF COMPLEX-III. NEUROPATH APPL NEURO , 13 (6) 497 - 497.

1986

MORGANHUGHES, JA; COOPER, JM; SCHAPIRA, AHV; CLARK, JB; (1986) MITOCHONDRIAL MYOPATHIES. MUSCLE NERVE , 9 (5) 78 - 78.

Schapira, AH; Thomas, PK; (1986) A case of recurrent idiopathic ophthalmoplegic neuropathy (Miller Fisher syndrome). J Neurol Neurosurg Psychiatry , 49 (4) 463 - 464.

SCHAPIRA, AHV; COOPER, JM; MORGANHUGHES, JA; CLARK, JB; (1986) EVIDENCE FOR MOLECULAR HETEROGENEITY IN HUMAN COMPLEX-I DEFICIENCY. MUSCLE NERVE , 9 (5) 183 - 183.

1985

SCHAPIRA, AHV; GALE, AN; (1985) PSEUDOMONAS OSTEITIS CAUSING CRANIAL NERVE PALSIES. J NEUROL NEUROSUR PS , 48 (12) 1306 - 1307.

SCHAPIRA, AHV; HUTTON, RA; (1985) PLATELET-AGGREGATION IN MYOTONIA. J NEUROL SCI , 71 (2-3) 351 - 357.

1981

Schapira, AH; (1981) Myasthenia gravis: a case report. Age Ageing , 10 (3) 198 - 199.

SCHAPIRA, AHV; (1981) HOW DOES LIGNOCAINE PREVENT VENTRICULAR-FIBRILLATION. LANCET , 2 (8256) 1167 - 1168.

1980

BAKER, PF; SCHAPIRA, AHV; (1980) ANESTHETICS INCREASE LIGHT-EMISSION FROM AEQUORIN AT CONSTANT IONIZED CALCIUM. NATURE , 284 (5752) 168 - 169.

SCHAPIRA, AHV; DYSON, PHP; (1980) VANCOMYCIN DOSE FOR PSEUDOMEMBRANOUS COLITIS. LANCET , 2 (8187) 204 - 204.

1977

BAKER, PF; SCHAPIRA, AHV; (1977) MEASUREMENT OF IONIC-DIFFUSION AND MOBILITY IN AXOPLASM ISOLATED FROM AXONS OF MYXICOLA. J PHYSIOL-LONDON , 266 (1) P5 - P5.

NULL

Blamire, AM; Cooke, F; Manners, DN; Korlipara, LVP; Styles, P; Schapira, AHV; ... Cooper, JM; + view all MRS measurement of neuronal dysfunction in the CNS in Friedreich's Ataxia and relationship to disability. Archives of Neurology

This list was generated on Wed Oct 22 09:38:06 2014 BST.

Page last modified on 20 mar 13 17:22